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ABSTRACT 
 
 Autism is a lifelong neurodevelopmental disorder. The etiology of autism still 
remains unclear due to the heterogeneous and complex nature of the disorder, however 
synergistic actions between genetic components and environmental factors have been 
suggested. Acetaminophen (APAP) is one of the most popular over-the-counter drugs 
that possess antipyretic and analgesic effects. It is considered a relatively safe and 
effective within therapeutic doses.  Recently, early exposure to APAP has been 
suggested to be one of the underlying cause of autism. Children are often prescribed 
APAP to lessen fever or irritability after vaccination during the first year, and APAP may 
adversely affect the normal brain development.  In order to better understand the 
association with APAP and autism, we used an inbred mouse strain BTBR T+tf/J 
(BTBR). BTBR exhibits behavioral deficits that mimic the core behavioral deficits of 
human autism. In the study, investigated 1) if BTBR mice showed differences in thiol 
biochemistry and EAAT3 levels in brain compared with C57BL/6J (C57) mice, 2) if early 
exposure to APAP induced behavioral changes worsening the autistic phenotypes of 
BTBR in adolescence, and 3) if APAP exposure in neonatal mice induced possible 
toxicity at various doses. As a result, we observed that BTBR mice have significantly 
lower plasma sulfate levels and EAAT expression levels in the frontal cortex compared 
to C57 mice. Surprisingly, neonatal therapeutic dose of APAP administration did not 
induce behavioral changes in both C57 and BTBR in adolescence. However, we 
vi 
showed that a supratheraputic dose of APAP significantly elevated levels of oxidative 
stress marker in the brain. Overall, the results suggested that BTBR mice would be a 
useful mouse model to investigate effects of various environmental factors that have 
been associated with autism. In addition, early exposure to APAP at supratherapeutic 
doses may negatively affect normal brain development.  
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CHAPTER 1 
INTRODUCTION 
 
1.1      Autism Spectrum Disorders 
Autism spectrum disorder (ASD) is a lifelong neurodevelopmental disorder that 
can start early in development, even before the age of three. Autism spectrum disorders 
include pervasive developmental disorder not otherwise specified (PDD-NOS), 
Asperger syndrome and autism. Due to the highly heterogeneous nature in the types of 
symptoms and degrees of the symptoms, ASD is referred to as a spectrum. 
Nonetheless, there are some overlapping symptoms that are common in autistic 
patients; including abnormal social behavior, impairment in verbal/non-verbal 
communication, and repetitive/stereotypic behaviors (Becker et al., 2013; Chen et al., 
2016; Klaiman et al., 2015). Multiple comorbidities, such as epilepsy, intellectual 
disability, hyperactivity and gastrointestinal symptoms are also seen in autistic 
individuals (Bitsika et al., 2015; Klaiman et al., 2015). Even though there is no definitive 
cure for ASD, the symptoms can be treatable. However, these behavioral impairments 
are still challenging and require attentive care and support.  
A survey by the National Center for Health Statistics of Center for Disease 
Control reported that 1 in 45 children have been diagnosed with ASD among the ages 
of 3 to 17 in 2014 (Zablotsky et al., 2015). ASD is the most prevalent developmental 
neurological disorder and the prevalence is estimated to increase with time, thus 
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drawing the attention of researchers, clinicians, and caregivers in the field. Currently, 
various treatments and therapies are used to control co-morbidities and behavioral 
impairments. Special education systems, medical treatments, and behavioral 
interventions are often needed for ASD patients.  These treatments, which cost 
approximately 60,000 US dollars for one autistic person without intellectual disabilities 
and 85,000 to 107,000 US dollars for ASD patients with intellectual disabilities per year 
(Amendah et al., 2011; Buescher et al., 2014). The economic cost in the U.S. for ASD is 
estimated to be 268 billion US dollars in 2015 and it is anticipated to be increased to 
461 billion US dollars by 2025 as ASD prevalence continues rise (Leigh et al., 2015). 
Early diagnosis of ASD remains difficult not only because of the heterogeneity of 
the disorder, but is also extensive to its unknown etiology. A large number of genes are 
associated with ASD which further clouds the etiology of the disease. Some 
main/common examples of ASD associated gene mutation include CNTNAP2, NLGN1, 
NLGN3, NLGN4, NRXN1, SHANK1, SHANK2, SHANK4, PTEN, FMR1, and MECP2 
(Buescher et al., 2014; Ergaz et al., 2016; Jiao et al., 2012; Kazdoba et al., 2016). 
Although genetic factors have been suggested as the underlying cause of autism, 
pathogenesis of autism is still not well defined as these genes do not account for many 
of the ASD cases (Kazdoba et al., 2016). Furthermore, only about 10% of autism cases 
have been associated with genetic factors (Chauhan et al., 2015; Deth et al., 2014). 
Therefore, it is strongly suggested that environmental & genetic factors may contribute 
together in autism pathogenesis (Koufaris et al., 2015). Research supports the 
hypothesis that prolonged exposure to certain environmental factors, including diet, air 
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pollution, pesticides, drugs, infections and heavy metals (Koufaris et al., 2015) may 
predispose genetically vulnerable individuals to develop autism.   
 
1.2      Animal model of autism  
ASD is characterized by distinct behavioral phenotypes which include impaired 
social interaction, deficits in verbal/non-verbal communication and repetitive stereotypic 
behaviors (Bitsika et al., 2015). Individuals are evaluated and diagnosed strictly based 
on those behavioral impairments using the fifth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) (Zablotsky et al., 2015). Animal models of human 
clinical conditions are useful to investigate underlying biological mechanisms of certain 
diseases; this aids the development of diagnostic and therapeutic strategies. Several 
murine models representing autism have been developed and investigated using gene 
mutations associated with the disorder as well as environmental factors (Ergaz et al., 
2016). However, it is not easy to develop an animal model that accurately reflects what 
is seen in ASD due to the given heterogeneity and complexity of autism.  These animal 
models often exhibit different types/severity of certain behaviors. In addition, ASD does 
not have specific biomarkers that can be used to diagnose the disorder; thus, it is 
harder to make an animal model that precisely mimics human clinical condition only 
based on behavioral phenotypes. Therefore, developing a more suitable animal model 
for ASD is imperative.  
An established mouse model for ASD, the BTBR T+tf/J (BTBR) inbred mouse 
strain,  is considered a strong animal model because it exhibits the three core 
behavioral abnormalities seen in humans with autism (Blanchard et al., 2012; 
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MacPherson et al., 2008; Meyza et al., 2013; Sforazzini et al., 2016). The behavioral 
phenotypes of the BTBR strain were first reported to be similar to human autistic 
phenotypes in 2007 (Moy et al., 2007), and continue to be extensively investigated. 
These mice consistently exhibit low sociability, abnormal communication, and 
stereotypic repetitive behavior (Amodeo et al., 2012; Blanchard et al., 2012; Sforazzini 
et al., 2016). Besides the behavioral phenotypes, complete corpus callosum agenesis 
and reduced hippocampal commissure are key structural characteristics seen in the 
brain of the BTBR strain (Bohlen et al., 2012; Ellegood et al., 2013; Meyza et al., 2013; 
Sforazzini et al., 2016; Stephenson et al., 2011). The corpus callosum and hippocampal 
commissure are white matter bundles composed of axons that interconnect the right 
and left cerebral hemispheres. The distinct function of the corpus callosum remains 
uncertain, but it has been reported that abnormalities within this region of brain are 
associated with behavioral deficits that can be seen in autism, ADHD, and 
schizophrenia (Dougherty et al., 2015; Erbetta et al., 2015; Goddard et al., 2015; 
Hanaie et al., 2014; Hinkley et al., 2012; Wolff et al., 2015). Additionally, it has been 
reported that corpus callosum integrity is associated with cognitive impairment that we 
can see in the elderly population (Hinkley et al., 2012; MacPherson et al., 2008). While 
recent evidence has shown that corpus callosum agenesis is not directly associated 
with the cause of autism, it cannot be excluded as a possible contributor to ASD since 
the behavioral deficits with callosal agenesis/partial absence overlap with some of 
autistic behaviors; such as, intellectual disability, delayed development, and anxiety. 
(Bloom et al., 2005; Chen et al., 2016; Fenlon et al., 2015; Hinkley et al., 2012; 
MacPherson et al., 2008; Yang et al., 2009).  
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It has reported that BTBR mice showed reduced plasma sulfate levels compared 
to C57BL/6J (C57) mice. Autistic patients and BTBR mice also show decreased 
heparan sulfate, a highly sulfated glycosaminoglycan, in subventricular zone (SVZ) of 
the lateral ventricles (LV) (Blanchard et al., 2012; Corley et al., 2012; Mercier et al., 
2012; Meyza et al., 2012; Pearson et al., 2013). It has demonstrated that mice with 
reduced heparan sulfates synthesis developed autistic behavioral impairments (Irie et 
al., 2012). Heparan sulfate synthesis within neurons is regulated by the ExT1 gene.  
Using Ext1 knockout mice, they observed that these mice exhibited no differences in 
their morphology in the brain, but developed autistic behavioral impairments that are 
seen in human autistic patients. These deficits included social behavior, vocalization 
and stereotyped/repetitive behaviors, as well as alterations in anxiety behaviors and 
hypersensitivity to thermal stimuli; implying that heparan sulfate synthesis is essential in 
normal brain development. 
In addition, research focused on other mechanisms/pathways has supported the 
impact of heparan sulfate on autism pathology. Gene deletion of sulfotransferases, 
specifically Hs2st or Hs6st1, resulted in disruption in the normal corpus callosum 
development at embryonic day 18.5, adding support to the fact that impaired heparan 
sulfate physiology can affect functional connectivity in the brain resulting abnormal brain 
development (Clegg et al., 2014; Conway et al., 2011). Taken all together, it is possible 
that significantly reduced sulfate levels in the BTBR strain may cause disruption in 
heparan sulfate formation contributing to callosal agenesis. Recently, a study using 
proteomic analysis to compare cortical tissue of BTBR and C57 mice; they reported 
differences in protein expressions that are associated with homeostatic processes, 
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neurotransmission, myelination and mitochondrial function (Wei et al., 2016).   Overall, 
the BTBR strain has become a useful animal model to explore links between the 
behavioral phenotypes and the underlying mechanisms of autism pathophysiology. 
While focusing on characterizing behavioral phenotypes of the BTBR strain as a model 
of autism. Additional biochemical and physiological characterizations in these animals 
still need to be explored to understand idiopathic autism pathophysiology. 
 
1.3      Detoxification of xenobiotics and sulfation  
It has been suggested that sulfate insufficiency may contribute to autism in 
certain populations due to the reduced capability for detoxification of various toxic 
compounds. Sulfate converts toxic compounds to non-toxic sulfoconjugates by sulfation.  
Sulfur exists as sulfate (SO4-) in animals. The level of sulfate is maintained by 
dietary sulfur-containing protein intake, of which most are composed of amino acids, 
methionine and cysteine (Bowling et al., 2013). In the liver, most drugs and xenobiotics 
are metabolized through phase 2 detoxification mechanisms, glucuronidation and/or 
sulfation.  
Drugs are metabolized through liver enzymes as phase 1 detoxification.  
Metabolites and remaining portions of the parent drug are further metabolized using 
phase 2 detoxification mechanisms by forming conjugations. Glucuronidation is 
catalyzed by a glucuronosyltransferase which moves the glucuronic acid of its substrate 
Uridine 5'-diphospho-glucuronic acid (UDT-glucuronic acid) onto xenobiotics (Fujiwara 
et al., 2016). Sulfation occurs via phenolsulfotransferases adding sulfate group to 
foreign substances (Kern et al., 2013). In adults, glucuronidation is primarily responsible 
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for detoxification; but in pediatric population, sulfation is the major route for the 
clearance of drugs (Arana et al., 2001). It has been suggested that autism patients have 
lower sulfation capacity and increased sulfate excretion implying possible sulfate 
deficiency in certain populations of autism patients (Hartzell et al., 2012). In addition, the 
insufficient sulfation capability with phenolic amines has been reported, suggesting 
abnormal neurotransmitter biotransformation, especially with catecholamines, leading to 
neurotoxicity. Taken together there may be an important role of sulfur in the pediatric 
population, and specifically those with ASD. 
In the process of detoxification, sulfate is converted to 3’-phosphoadenosine-5’-
phosphosulfate (PAPS), the universal sulfur donor in animals. PAPS donates sulfuryl 
groups to compounds catalyzed by phenolsulfotransferase, producing a sulfated 
compound and 3’-phosphoadenosin-5’-phosphate (PAP) (Klaassen et al., 1997a; 
Klaassen et al., 1997b). Acetaminophen (APAP), a popular antipyretic, that is often 
used after early age vaccinations, needs to be sulfated by PAPS to be secreted via the 
kidney (Klaassen et al., 1997a). In the pediatric population, inadequate sulfate levels 
lead to greater amounts of APAP being metabolized by cytochrome P450 2E1 (CYP 
2E1). This alternative route of metabolism generates more of the toxic metabolite, N-
acetyl-p-benzoquinonimine (NAPQI). NAPQI overproduction is known to cause 
glutathione (GSH) depletion. GSH is a tripeptide that is composed with cysteine, 
glutamic acid and glycine, and is one of the essential cellular antioxidant, and also plays 
an important role in detoxification of xenobiotics and cellular protection against 
electrophilic compounds. NAPQI forms covalent bonds with GSH, lowering its 
availability, and result in severe liver damage (A. Abdin, 2013). The ratio of APAP-
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sulfate conjugates and APAP-glucuronide conjugates was significantly lower in severe 
autism patients suggesting insufficient sulfation for detoxification (Alberti et al., 1999).  
In detoxification, GSH forms covalent bonds with xenobiotics and nucleophiles 
via glutathione-s-transferase (GST) forming mercapturic acids, making the compounds 
inactive (Pocernich et al., 2012; Townsend et al., 2003). Furthermore, low levels of 
plasma inorganic sulfate and GSH levels have been reported in autistic individuals 
(Adams et al., 2011; Wood, 2014). Both sulfate and GSH are critical for detoxification 
and lower levels are associated with increased in xenobiotic induced cellular toxicity and 
oxidative stress (Hartzell et al., 2012). Several studies found that autistic individuals 
have abnormal sulfate chemistry, insufficient thiol levels, and decreased GSH, which 
make individuals more vulnerable to environmental toxins due to the imbalance in redox 
state and reduced detoxification capacity (James et al., 2004; James et al., 2006; Kern 
et al., 2013).  
 
1.4      Acetaminophen  
APAP is an analgesic and antipyretic agent that effectively relieves pain and 
fever in all age groups (Ishida et al., 2007; Kis et al., 2005). It is also used for treating 
the common cold, headaches, toothaches, body aches, and menstrual cramps.  APAP 
can serve as an effective antipyretic in infants and children as well (Shaheen et al., 
2010). In a human study, the half-life of APAP was prolonged in neonates and younger 
children compared to adults, which can increase its possible accumulation in the plasma 
(Arana et al., 2001); thereby making pediatric population more vulnerable to APAP 
associated side effects. APAP is mainly metabolized in the liver and excreted via the 
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kidney by conjugating with glucuronic acid and sulfate (Fig. 1.1). In the liver, about 10 to 
15% of APAP is metabolized by cytochrome P450 enzymes (mainly the CYP 2E1 
isoform). This subsequently generates its toxic metabolite, NAPQI.  NAPQI is then 
mercapturated by GSH and is excreted via the kidney. Excessive amounts of NAPQI 
can deplete GSH, leading to disrupted redox homeostasis (Anderson, 2008; Blecharz-
Klin et al., 2014). In addition, NAPQI is a strong electrophile that can bind with 
biomolecules such as DNA, proteins and lipids, and lead to cellular damage and 
ultimately, liver failure with APAP overdose (Gum et al., 2013; Kalinec et al., 2014; 
Nassini et al., 2010). Although less studied than hepatotoxicity, it has been shown that 
APAP is able to cross the BBB where it can be metabolized by CYP 2E1, suggesting 
potential neurotoxicity (Fischer et al., 1981). Studies have shown that 4AP, another 
APAP metabolite formed in the liver, can cause renal failure without inducing severe 
liver damage by acting in three different ways (Harmon et al., 2006; Mach et al., 2014; 
McConkey et al., 2009). First, 4AP is converted to electrophilic compounds by CYP 2E1 
in kidney (Newton et al., 1982). Second, production of GSH-4AP conjugate leading to 
GSH depletion. Third, N-deacetylase catalyzes APAP conversion to 4AP and produces 
free radicals. In the brain, 4AP is converted to N-arachidonoylphenolamine (AM404) by 
conjugating with arachidonic acid. This reaction is catalyzed by fatty acid amide 
hydrolase (FAAH). AM404 is known to inhibit reuptake of anandamide, an endogenous 
cannabinoid, thereby exerting its analgesic effect (Becker et al., 2010; Hogestatt et al., 
2005; Schultz et al., 2008). It has been suggested that APAP alters the brain 
endocannabinoid system during early development, resulting in behavioral changes 
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associated with developmental disorders such as ADHD and autism (Becker et al., 
2010; Schultz et al., 2008; Shaw, 2013).   
In the US, about 79% of the population takes APAP regularly and about 35% of 
women take APAP during pregnancy (Posadas et al., 2007). During the first year, 
children are often prescribed APAP to lessen fever or irritability after vaccination. In 
addition, epidemiological studies suggested that APAP administration during pregnancy 
may result in ADHD-like behavior (Liew et al., 2014) and APAP administration after 
vaccination may increase the risk of autism (Shaw, 2013). In fact, Posadas et al. (2010) 
showed that APAP induces apoptosis of rat cortical neurons both in vitro and in vivo at 
lower doses than that known to induce liver damage. Moreover, da Silva et al. (2012) 
showed increased oxidative stress and disrupted mitochondrial function in mouse brain 
after toxic dose of APAP administration, implying acute neurotoxicity. It has also 
reported that brain amino acids levels were changed with chronic administration of 
therapeutic doses of APAP, suggesting that it induces altered neurotransmission, which 
may be involved in neurobehavioral changes (Blecharz-Klin et al., 2014). However, the 
available research is inadequate to explain APAP-induced changes during brain 
development that could lead to developmental disorders. 
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Figure 1.1 APAP metabolism. APAP is first metabolized in the liver by CYP450 2E1. 
During this process, the toxic metabolite NAPQI is generated. Within the therapeutic 
dose, NAPQI can conjugate with GSH and cysteine. However when overdosed, NAPQI 
overproduction results in GSH depletion leading to tissue damages. APAP also pass 
through phase 2 detoxification; glucuronication and sulfation. Some portion of the 
remaining APAP can be deacetylate into 4AP.  
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1.5      Oxidative stress  
Even though the brain is only 2% of the total body weight, it’s high oxygen 
consumption (approximately 20%) can result in the production of excess free radical by-
products. Also, the brain has a high concentration of polyunsaturated fatty acid, 
contains oxidizing metals such as Cu2+ and Fe2+, and has relatively low superoxide 
dismutase, catalase, and glutathione peroxidase activity compared to other organs. 
Thus, the brain is more prone to oxidative stress (Berk et al., 2008; Schmidt et al., 
2012).  
Oxidative stress presents when the equilibrium of free radical formation and 
removal is not balanced. Free radicals, such as reactive oxygen species (ROS) and 
reactive nitrogen species (RNS), are generated during normal oxidative metabolism. 
The inability to remove these free radicals, which can include superoxide anion, 
hydrogen peroxide, hydroxyl radical, nitric oxide (NO) and peroxynitrite, can damage 
biomolecules that are essential to normal physiological function (Oztop et al., 2012; 
Raymond et al., 2014; Wilkins et al., 2013). 
Increases in oxidative stress and reductions of antioxidant capacity in autism 
have been extensively studied (Chauhan et al., 2015; Gu et al., 2013; James et al., 
2004). Oxidative stress, caused by the imbalance of redox states, can result in cellular 
stress and cytotoxicity (Schmidt et al., 2012). Increased oxidative stress is strongly 
associated with numerous neurological disorders including autism (Ehrhart et al., 2015; 
Gaki et al., 2014; Kim et al., 2015; Kulak et al., 2012; Zhang et al., 2014) .   
Aforementioned, GSH is important for protecting cells against oxidative stress 
and detoxification. GSH maintains cellular reduction-oxidation balance by reducing free 
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radicals. Since GSH can scavenge free radicals both enzymatically and non-
enzymatically, it is the primary cellular defense system to maintain redox homeostasis in 
the brain. GSH reacts with free radicals via glutathione peroxidase (GPx), resulting in 
the generation of glutathione disulfide (GSSG), the oxidized form of GSH. GSSG is then 
converted back to two molecules of GSH via glutathione reductase (GR) utilizing 
NADPH (nicotinamide adenine dinucleotide phosphate) as a cofactor; thus, balancing 
cellular redox status. In addition to its antioxidant properties, GSH is also involved in 
detoxification of xenobiotics and protection of cells against nucleophiles via glutathione-
s-transferase (GST). GSH forms covalent bonds with xenobiotics and nucleophiles, 
inactivating these compounds (Pocernich et al., 2012; Townsend et al., 2003). As stated 
above, GSH exists in cells as both a reduced (GSH) and oxidized (GSSG) form, and the 
optimal GSH/GSSG ratio needs to be maintained for normal cellular function (Johnson 
et al., 2012; Zhou et al., 2014). Abnormal GSH/GSSG indicates an imbalance in cellular 
redox homeostasis. Cells depleted of GSH are more vulnerable to oxidative stress, and 
it is well known that the disrupted GSH system and increased oxidative stress is 
strongly associated with neurodegenerative diseases as well as neuropsychiatric 
diseases such as anxiety, bipolar, schizophrenia and substance abuse (Aoyama et al., 
2012; Berk et al., 2008; Townsend et al., 2003). Additionally, low GSH/GSSG has been 
reported in plasma (Gu et al., 2013; Heberling et al., 2015) and brains (Gu et al., 2013) 
of autism patients. 
GSH levels are maintained by intracellular de novo synthesis through two 
coupled enzyme reactions (Fig. 1.2) (Johnson et al., 2012). First, cysteine and glutamic 
acid form a di-peptide through γ-glutamylcysteine ligase (GCL) followed by glycine 
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addition to form GSH by GSH synthetase (GS). In this reaction, Cysteine is the rate-
limiting component due to its relatively lower concentration compared to glutamic acid 
and glycine (Aoyama et al., 2008; Le et al., 2011). Interestingly, in neurons, the majority 
of cysteine has to be transported from the extracellular space through one of the 
excitatory amino acid transporters (EAATs) (Cao et al., 2012; Crino et al., 2002). 
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Figure 1.2 GSH synthesis and function in neurons. GSH de novo synthesis occurs 
in two enzymatic reactions. Cysteine is transported through EAAT3 in neurons and then 
added onto glutamic acid forming γGC using GCL. The second step is the addition of 
glycine via GS to form the final product, GSH. GSH is then used as antioxidant through 
GPx converting H2O2 into H2O. Furthermore, GSH is used in detoxification when GST 
forms mercapturic conjugates with various foreign substances.  
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1.6      Excitatory amino acid transporter 3 
GSH is a major antioxidant and the deficit in GSH homeostasis is linked to 
etiology of many neurological disorders including schizophrenia, autism, Parkinson’s 
disease and other neurodegenerative diseases (Aoyama et al., 2013; Berk et al., 2008; 
Townsend et al., 2003). In the brain, GSH is mainly generated from astrocytes and then 
transported into extracellular spaces to be used by other types of cells (Rae et al., 
2016). There are no known GSH transporters in neurons, therefore GSH is further 
catabolized by ectoenzyme aminopeptidase to be broken apart into glutamylcysteine, 
cysteine, glycine and/or glutamic acid (Baxter et al., 2016; Shih et al., 2003). Synthesis 
mainly relies on cysteine availability, as cysteine is the rate-limiting component in the 
GSH de novo synthesis.  About 90% of the cysteine is supplied from extracellular space 
through the excitatory amino acid transporter 3 (EAAT3) in neurons (Johnson et al., 
2012). EAAT3 may therefore have an essential role in neuroprotection against oxidative 
stress 
 EAATs are Na+-dependent glutamate transporters. EAATs require transport of 3 
Na+ and 1 H+ into the cells and 1 K+ out of the cells. There are five EAATs (EAAT 1-5) 
for balancing extracellular glutamate levels in CNS. Among the five transporter families, 
EAAT3 (also termed EAAC1 and Slc1a1, solute carrier family 1 member 1) is a neuron-
specific transporter found throughout the nervous system and is localized in cell bodies 
as well as processes. About 20% of EAAT3 transporters are expressed at the plasma 
membrane in a resting state and it is increased by translocation upon stimulation due to 
oxidative stress and excitotoxicity (Escartin et al., 2011). EAAT3 is involved in the 
glutamate reuptake from extracellular space, which is used to produce γ-aminobutyric 
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acid (GABA) in GABAergic neurons in the cortex and hippocampus. This indicates 
EAAT3 may have an important role in neurotransmission regulation (Guo et al., 2015; 
Raiteri et al., 2015). EAAT3 is unique, compared to other EAATs in the family, due to 
the ability to transport cysteine into neurons (Aoyama et al., 2008; Cao et al., 2012). 
EAAT3 is known to mediate cysteine transport to supply cysteine for neuronal GSH 
synthesis; therefore, participating in neuroprotection (Robert et al., 2014). EAAT3 
knockout mice have decreased dopaminergic neurons, and n-acetylcysteine (NAC) 
treatment restored the loss of dopaminergic neurons by increasing thiol content 
(Escartin et al., 2011). EAAT3 knockout mice were also more vulnerable to oxidative 
stress due to the GSH depletion by MPTP treatment, and NAC had protective effects 
against MPTP induced oxidative stress by replenishing GSH (Aoyama et al., 2006). In 
addition, it has demonstrated that NAC opposed the age dependent dopaminergic 
neuron loss in substantia nigra pars compacta and significantly elevated activated 
microglia as well as nitrotyrosine and nitrated α-synuclein in EAAT3 knockout mice 
(Berman et al., 2011).  
The EAAT3 expression can be fluctuated by various factors resulting in GSH 
homeostasis. It has been shown that chronic postnatal stress causes decreased EAAT3 
expression in the hippocampus and frontal cortex in adolescent rats (Odeon et al., 
2015), and chronic morphine exposure resulted in decreased EAAT3 expression in rat 
hippocampal neurons (Guo et al., 2015). It has been demonstrated that proline rich 
opioid peptides, derived from casein and gliadin, modulate cysteine uptake in human 
neuroblastoma cells and colon carcinoma cells.  Additionally, decreases in  GSH/GSSG 
and SAM/SAH were observed as well, resulting  in oxidative stress due to decreased 
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cysteine uptake through EAAT3 transporters (Trivedi et al., 2014). Furthermore, 
genome wide promoter methylation was significantly increased by casein derived opioid 
peptide similar to morphine treatment in accordance with cysteine uptake inhibition, 
suggesting EAAT3 mediated cysteine uptake modulation and redox balance are 
associated with epigenetic regulation of gene expression as well.  
Neuregulin induced neuronal cobalamin production is regulated by intracellular 
neuronal glutathione levels which depend on cysteine uptake through EAAT3 (Zhang et 
al., 2015).  This implies that EAAT3 mediated cysteine uptake is important during 
neurodevelopment modulating an essential neurohormone associated with normal 
growth and differentiation. Also the study showed that wortmanin, the PI3K inhibitor, 
opposed neuregulin 1 effects on maintaining glutathione balance and promoting 
cysteine uptake.  This suggests that EAAT3 mediated cysteine uptake and subsequent 
glutathione production is possibly mediated by PI3K/AKT signaling cascade.  
Besides the unique feature of EAAT3 as an exclusive neuronal cysteine 
transport, EAAT3 is involved in glutamate uptake near GABAergic neurons utilizing 
glutamate to generate GABA via enzyme for balanced neurotransmission (Crino et al., 
2002; Guo et al., 2015; Holmseth et al., 2012). It has been suggested that abnormal 
GABA function may be associated with autism (Coghlan et al., 2012; Han et al., 2014; 
Robertson et al., 2016). Lower GABA transmission is linked to multiple symptoms; such 
as hyperkinesia, seizures, mental retardation, hyperactivity, which can be frequently 
seen in autism as co-morbid symptoms (Hendren et al., 2009). It has been 
demonstrated that cellular prion protein is associated with EAAT3 mediated glutamate 
uptake as well as cysteine transport in cells (Guitart et al., 2015). In this study, cell 
 19 
viability with and without the EAAT3 inhibitor, L-aspartate-β-hydroxamate, was 
compared under oxidative stress conditions as well as glutamate excitotoxicity. As a 
result, EAAT3 inhibition increased cell death suggesting EAAT3 plays a role in 
protecting neurons by regulating glutamate excitotoxicity and oxidative stress. Sodium 
dependent cysteine uptake was increased when prion protein was presented under an 
oxidative stress environment, but did not increase cysteine transport under normal 
conditions. This suggests EAAT3 and prion protein interplay is essential when cells are 
under oxidative stress.   
EAAT3 activity is regulated by nuclear factor erythroid 2-related factor 2 (Nrf2) 
(Escartin et al., 2011). The Nrf2/ARE (antioxidant response element) complex is 
involved in cell survival in response to oxidative stress by regulation of gene expression 
encoding antioxidant proteins (Steele et al., 2013), which are involved in various phase 
2 detoxification genes such as GCL, GPx and GST to balance redox homeostasis 
(Harvey et al., 2009; Maes et al., 2012; Mitsuishi et al., 2012; Wang et al., 2013); 
therefore, addressing the importance of EAAT3 in neurons against oxidative stress 
induced neurotoxicity by regulating glutathione redox homeostasis.  
 
1.7      Objectives 
Taken together, the objective was to determine if the commonly used ASD 
mouse model, BTBR, would be more vulnerable to environmental factors due to the 
diminished detoxification and antioxidant capacity compared to C57. Our hypothesis 
was that the BTBR strain has lower plasma sulfate, brain EAAT3 expression and GSH 
levels, thus making the strain more prone to oxidative stress induced by neonatal 
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exposure to APAP. In chapter 2, BTBR strain was compared to C57 in terms of plasma 
sulfate, brain EAAT3 expression and GSH levels. In chapter 3, we evaluated if the early 
exposure to APAP exacerbated autistic symptoms in BTBR and C57 strains. In chapter 
4, we determined the toxic effects of early exposure to APAP in both BTBR and C57 
strains. 
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CHAPTER 2 
Altered EAAT3 Expression and Plasma Sulfate Levels in the BTBR Mouse Model 
of Autism 
 
 
2.1     Introduction  
Autism is a neurodevelopmental disorder that is characterized by behavioral 
deficits including abnormal social behavior, impairment in verbal/non-verbal 
communication, and repetitive/stereotypic behaviors (Becker et al., 2013; Chen et al., 
2016; Klaiman et al., 2015). Multiple comorbidities, such as epilepsy, hyperactivity, and 
gastrointestinal symptoms are seen in autistic individuals, and symptoms are highly 
heterogeneous (Bitsika et al., 2015; Klaiman et al., 2015). While genetic factors have 
been suggested as the underlying causes of autism, pathogenesis of autism is not well 
defined and a large number of genes seem to be involved. However, only about 10% of 
autism cases have been associated with genetic factors (Chauhan et al., 2015; Deth et 
al., 2014); therefore, it is strongly suggested that in addition to genetic factors, 
environmental factors also contribute to autism pathogenesis.  
Animal models are useful tools to investigate underlying biological mechanisms 
of diseases. The inbred murine strain, BTBR T+tf/J (BTBR), is considered a strong 
animal model of autism because it exhibits three core behavioral abnormalities seen in 
humans with autism; a disease that is diagnosed purely by behavioral deficits 
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(Blanchard et al., 2012; MacPherson et al., 2008; Meyza et al., 2013; Sforazzini et al., 
2016). Behavioral characteristics of BTBR mice have been extensively investigated and 
these mice consistently exhibit impaired social interaction, abnormal vocalization, and 
stereotypic repetitive behavior (Blanchard et al., 2012; Corley et al., 2012). This strain 
also exhibits similar neuroanatomical hallmarks of autism, such as agenesis of the 
corpus callosum and reduced hippocampal commissure (Blanchard et al., 2012; Meyza 
et al., 2012; Meyza et al., 2013). Moreover, evidence has been reported for impaired 
sulfation, with significantly lower plasma sulfate levels (Corley et al., 2012) and 
decreased brain levels of heparan sulfate (Blanchard et al., 2012; Meyza et al., 2012) in 
comparison to the inbred C57 mouse strain, a commonly used comparison strain to the 
BTBR. These findings are consistent with reports of heparan sulfate deficiency in 
autistic postmortem brain tissue (Pearson et al., 2013) as well as abnormal sulfation 
capacity (Waring et al., 1997) and decreased sulfate conjugation of acetaminophen 
found in autistic children (Alberti et al., 1999). Thus, the BTBR strain is a valid animal 
model to explore links between the behavioral phenotypes and the possible underlying 
causes of autism.  
In the liver, xenobiotics are metabolized through glucuronidation and/or sulfation, 
both phase 2 detoxification mechanisms. While glucuronidation is more responsible for 
detoxification in adults, sulfation is the major metabolic pathway in newborns (Arana et 
al., 2001), suggesting an important role of sulfur in the pediatric population. The level of 
sulfate is maintained by dietary sulfur-containing protein composed of amino acids 
methionine and cysteine (Bowling et al., 2013). Low levels of plasma inorganic sulfate 
and glutathione (GSH) have been reported in autistic individuals (Adams et al., 2011; 
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Wood, 2014).  In fact, lower levels of both sulfate and GSH are associated with 
increased xenobiotic induced cellular toxicity and oxidative stress (Hartzell et al., 2012).  
GSH is the main tri-peptide thiol that protects cells against oxidative stress 
(Schmidt et al., 2012). GSH reacts with free radicals via glutathione peroxidase (GPx), 
resulting in the generation of glutathione disulfide (GSSG), the oxidized form of GSH. 
GSSG is then converted back to GSH via glutathione reductase (GR), which uses a 
NADPH (Nicotinamide adenine dinucleotide phosphate) coupled enzymatic reaction 
(Dickinson et al., 2002). The ratio of GSH to GSSG indicates cellular redox states and 
optimal ratio needs to be maintained for normal cellular function (Johnson et al., 2012; 
Zhou et al., 2014). In addition, GSH is also involved in detoxification of xenobiotics and 
protection of cells against nucleophiles via glutathione-s-transferase, GST forming 
covalent bonds between GSH and xenobiotics or nucleophiles, rendering them inert and 
allowing for eliminiation from the body (Pocernich et al., 2012; Townsend et al., 2003). 
GSH levels are maintained by intracellular de novo synthesis through two coupled 
enzyme reactions (Johnson et al., 2012). First, Cysteine (Cys) and glutamic acid form a 
di-peptide through γ-glutamylcysteine ligase (GCL) followed by glycine addition by GSH 
synthetase (GS) to form GSH. In this reaction, Cys is the rate-limiting component due to 
its relatively lower systemic concentration compared to glutamic acid and glycine 
(Aoyama et al., 2008; Le et al., 2011). In neurons, the majority of Cys has to be 
transported from the extracellular space through one of the excitatory amino acid 
transporters (EAATs), EAAT3 (Cao et al., 2012; Crino et al., 2002). 
Unlike other EAATs, EAAT3 (also termed EAAC1 and Slc1a1- solute carrier 
family 1 member 1) is thought to be mainly involved in cysteine uptake rather than 
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glutamate clearance from the extracellular space (Aoyama et al., 2008; Cao et al., 
2012). At a resting state, about 20% of EAAT3 is expressed at the plasma membrane, 
but is increased by translocation from intracellular in response to oxidative stress and 
excitotoxicity (Escartin et al., 2011). It has been reported that chronic postnatal stress 
decreased EAAT3 expression in the hippocampus and frontal cortex of adolescent rats 
(Odeon et al., 2015) and  could have significant neurodevelopmental consequences. 
Odeon et al. (2015) showed that EAAT3 knockout mice were more vulnerable to 
oxidative stress and had greater loss of dopaminergic neurons following treatment with 
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). NAC (N-acetyl-cysteine), a well-
known antioxidant that does not require EAAT3 to get into the cell (Aruoma et al., 1989; 
das Neves Duarte et al., 2012), provided protection against MPTP induced oxidative 
stress. NAC also restored the loss of dopaminergic neurons by increasing thiol content 
(Escartin et al., 2011) and by replenishing GSH stores (Aoyama et al., 2006) in EAAT3 
knockout mice. These findings suggest that EAAT3 plays a pivotal role in maintaining 
intracellular GSH levels by supplying Cys for GSH de novo synthesis in neurons.  
Although numerous genes have been implicated in association with autism, the 
etiology of this disease is still unclear. Many researchers have proposed that prolonged 
exposure to certain environmental toxins, such as thalidomide, lead, and mercury, may 
predispose genetically vulnerable individuals with reduced detoxification capability to 
autism (Chauhan et al., 2015; Dufault et al., 2009; Kern et al., 2013; Stringari et al., 
2006). 
Cells depleted of GSH are more vulnerable to oxidative stress, and it is well 
known that a disrupted GSH system is strongly associated with neurodegenerative 
 25 
diseases, as well as neuropsychiatric disorders, such as anxiety, bipolar disorder, 
schizophrenia and substance abuse (Aoyama et al., 2012; Berk et al., 2008; Pearson et 
al., 2013). Indeed, low GSH/GSSG levels have been reported in the plasma (Gu et al., 
2013; Heberling et al., 2015) and brains (Chauhan et al., 2012; Gu et al., 2013; Rose et 
al., 2012) of autism patients. 
We hypothesize that some autistic children may have been more vulnerable 
neurodevelopmentally due to coincident reductions in both plasma sulfate and brain 
EAAT3 transporter levels, which increased environmental toxin induced oxidative stress 
and neurotoxicity. To test this hypothesis, the present study sought to investigate 
whether the BTBR mouse model of autism exhibits differences in thiol biochemistry and 
EAAT3 expression in brain when compared with C57 mice. 
 
 
2.2      Materials and Methods 
2.2.1   Animal housing and maintenance 
All procedures herein were in accordance with the animal protocol approved by 
the University of South Florida (USF) Institutional Animal Care and Use Committee 
(IACUC).  6 week old male BTBR T+tf/J and C57BL/6J mice were purchased from the 
Jackson Laboratory and mice were subjected to experiment at 7 weeks of age. Upon 
arrival, four littermates were housed per cage and mice were maintained in controlled 
conditions at 22 ± 2 ˚C on 12h light/dark cycle. Mice were acclimated for 7 days prior to 
the start of the experiment. Mice were provided with standard rodent chow and water ad 
libitum.  
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2.2.2   Tissue preparation  
Mice were anesthetized with CO2 and then blood samples were collected by 
cardiac puncture into EDTA containing tubes. Plasma was isolated by centrifugation at 
1500g for 30 min. After centrifugation, the upper plasma layer was carefully collected 
into new 1.5mL conical vials and stored at -20 °C for further biochemical analysis. Mice 
were then perfused transcardially with phosphate buffered saline (PBS), and brains 
were removed. The brains were divided sagittally into equal hemispheres. One 
hemisphere of each brain was fixed in 4% paraformaldehyde (PFA) for 
immunohistochemistry, and the other hemisphere of the brain was dissected to isolate 
the frontal cortex, and then rapidly frozen in liquid nitrogen before storage at -80 °C for 
Western blotting.  
 
2.2.3   Plasma inorganic sulfate analysis 
Inorganic sulfate levels in plasma were analyzed using QuantiChromTM Sulfate 
Assay Kit (BioAssay) according to manufacturer’s instruction. First, plasma samples 
were deproteinated with the TCA reagent by centrifugation and the supernatant was 
transferred to a 96 well plate. Next, the working reagent was mixed with the collected 
supernatant and absorbance was measured using a multimode plate reader (EnSpire®, 
PerkinElmer) set to read at a wavelength of 540nm. This method measures inorganic 
sulfate quantitatively by measuring the turbidity due to insoluble barium sulfate 
formation in polyethylene glycol. 
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2.2.4   GSH/GSSG analysis in the plasma and the brain  
GSH levels were measured by o-phthalaldehyde (OPA) derivatization using 
Glutathione Fluorometric Assay Kit (Biovision). GSSG levels were measured by 
reducing GSSG to GSH after quenching existing GSH activity. According to 
manufacturer’s instruction, plasma and brain homogenates were obtained and 
deproteinated with 6N perchloric acid. Samples were then neutralized with 6N 
potassium hydroxide prior to OPA addition for reaction. Fluorescent intensity was 
measure at Ex/Em = 340/420 nm.  
 
2.2.5   mRNA expression of  Slc1a1, Gclc, Gclm and Gsr in frontal cortex 
Real time qPCR was carried out to measure Slc1a1, Gclc, Gclm and Gsr in 
frontal cortices of BTBR and C57 mice (n=3). Tissue was collected and treated with 
RNAlater® RNA stabilization reagent (Qiagen). Total RNA extraction was performed by 
RNeasy® Mini kits (Qiagen) according to manufacturer’s instructions. RNA quantity and 
quality were assessed by the 260/280 nm absorbance ratio using Nanodrop™. 0.6 μg of 
total RNA was used to synthesize cDNA using RT2 First Strand Kit (Qiagen).  Primer 
sequences were obtained from Harvard University’s public database, PrimerBank. 
Primers used for amplification of gene transcripts were as follows: Slc1a1 Fwd 5’-TCG 
TFF TTC GAG GAC ACA GT-3’; Slc1a1 Rev 5’-CGA TCA GCG GCA AAA TGA CC-3’; 
Gclc Fwd 5’- GGG GTG ACG AGG TGG AGT A-3’; Gclc Rev 5’- GTT GGG GTT TGT 
CCT CTC CC-3’; Gclm Fwd 5’- AGG AGC TTC GGG ACT GTA TCC-3’; Gclm Rev 5’- 
GGG ACA TGG TGC ATT CCA AAA-3’;  Gsr Fwd 5’- GAC ACC TCT TCC TTC GAC 
TAC C-3’; Gsr Rev 5’- GGG ACA TGG TGC ATT CCA AAA-3’. The mouse Gapdh 
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primer was obtained from IDT PrimeTime® (Ref Seq # NM_008084(1)).  A master mix 
solution was prepared with 2.5 μL of PowerUp™ SYBR Green Master Mix, 0.15 μL of 
primers (stock conc. 10 μM) and 1.2 μL H2O per sample. 1 μL of cDNA and 4 μL of the 
master mix were added to each well in a 384 well plate (Thermo Fisher). All samples 
were run in triplicate by the BioRad CFX384™ Real-Time PCR Detection system. The 
data were analyzed using ΔCt and ΔΔCt calculations and expressions of all genes were 
normalized to mouse Gapdh.  
 
2.2.6   EAAT3 protein expression in brain  
EAAT3 protein expression levels were obtained via immunohistochemistry and 
Western blotting. For immunohistochemistry, brain tissues were fixed with 4% PFA 
overnight and immersed in a 30% sucrose solution for 2 days for dehydration. Tissues 
were then cryo-sectioned, resulting in 30-μm sections, with five sections per animal 
selected for immunostaining. Tissue sections were blocked with 4% normal goat serum 
and incubated with EAAT3 (Sigma, 1:500, Rabbit), NeuN (Abcam, 1:1000, Mouse) at 4 
˚C overnight. Tissue sections were incubated with Alexa Fluor® 488 conjugated goat 
anti-rabbit and Alexa Fluor® 594 conjugated goat anti-mouse secondary antibodies.  
Stained sections were mounted with DAPI hardset mounting media (S1400, 
VECTASHIELD). Fluorescence images were obtained at 20X magnification using a 
Zeiss (MRc) microscope. Cells expressing green fluorescence were counted as number 
of neurons, and cells expressing red puncta with green fluorescence were identified as 
EAAT3 expressing neuronal cells. Three fields were randomly chosen in frontal cortex 
 29 
of each tissue section and the ratio of EAAT3 positive neurons to total neurons was 
calculated by an individual blinded to groups.  
For Western blotting, the frontal cortex was dissected and snap frozen in liquid 
nitrogen. Tissues were homogenized in lysis buffer (Sigma), and supernatant was 
subjected to subcellular fractionation to obtain cytosolic and membrane by using 
subcellular fractionation kit (Pierce) according to manufacturer’s instructions. 30 μg of 
protein were loaded onto 10% SDS-PAGE gel and transferred onto nitrocellulose 
membrane. Membranes were then blocked with 5% non-fat dry milk and incubated with 
rabbit anti-EAAT3 antibody diluted with blocking buffer at 4 ˚C overnight. GAPDH and β-
actin were used for loading controls. After washing with 0.1% TBST, membranes were 
incubated with secondary antibodies for 1 hr and visualized with Odyssey® Infrared 
Imaging system. Band intensities were normalized to the protein concentration 
calculated by BCA assay. 
 
2.2.7   Statistical Analysis  
All data are presented in mean and standard error of mean (SEM). Statistical 
analysis was carried out using T-test and using Graphpad version 5.0.  
 
2.3      Results 
2.3.1   Plasma sulfate levels 
To measure the differences in plasma inorganic sulfate levels, plasma samples 
were collected from BTBR and C57 mice (n = 4). Sulfate levels were measured (Fig. 
2.1) by turbidimetric assay. As a result, the BTBR mice were found to have significantly 
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lower plasma sulfate levels (T-test, *p < 0.05) compared to C57 mice. This finding is in 
agreement with the findings from Corley et al. (Corley et al., 2012)  that has also 
demonstrated the BTBR mouse strain has reduced plasma sulfate levels.  
 
2.3.2   GSH/GSSG levels  
GSH and GSSG levels were measured in BTBR and C57 mice (n = 4) in plasma 
and frontal cortex homogenates (Fig. 2.2). GSH and GSSG levels were not significantly 
different between mouse strains in the frontal cortex. However, plasma GSSG levels 
were significantly higher in BTBR compared to C57 mice (T-test, *p < 0.05), but no 
significant differences were noted in GSH levels or GSH/GSSG ratios.  
Furthermore, we measured mRNA expression levels of Gclc (gene encodes GCL 
catalytic unit), Gclm (gene encodes GCL modifier) and Gsr (gene encodes GR) in 
frontal cortices of BTBR and C57 mice.  While mRNA expression levels of Gclm were 
lower in BTBR than C57 mice (T-test, *p < 0.05), Gclc levels were similar in both mouse 
strains (Fig. 2.3). GCL, a heterodimer that has catalytic unit and modifier unit, is also the 
enzyme that synthesizes Cys and glutamic acid as the rate limiting step of GSH 
biosynthesis (Fig. 1.1). While enzymatic activity of GCL is provided from Gclc, Gclm 
increases the efficiency of GCL enzymatic activity (Cole et al., 2011; Yang et al., 2002). 
Although we did not see significant changes in GSH levels in the brain, this lack of 
support for efficient GSH production system may lead BTBR mice to be prone to a 
greater degree of oxidative stress compared to C57 upon xenobiotics/oxidative 
stressors.  
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Gsr mRNA expression levels in BTBR mice were lower than those in C57 mice 
(Fig. 2.3). Such decreased Gsr mRNA expression may also be associated with reduced 
antioxidant capacity upon exposure to oxidants by accumulating GSSG as GR is the 
NAD(P)H-dependent enzyme that reduces GSSG to GSH (Fig. 1.1). Although we did 
not see differences in brain GSH and GSSG levels between two strains, our data 
suggests the possible dysregulation in GSH recycling system in BTBR mice.  
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Figure 2.1 Reduced levels of free sulfate in the plasma of BTBR versus C57 mice.   
Plasma free sulfate levels were measured using turbidometric method from BTBR and 
C57 mice. Interestingly, BTBR mice exhibited significantly lower plasma sulfate levels 
(T-test, *p < 0.05) suggesting that BTBR may be vulnerable to drugs and xenobiotic 
induced toxicity that require sulfation for detoxification. 
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Figure 2.2 GSH/GSSG levels in BTBR and C57 mice. BTBR and C57 showed similar 
levels of GSH and GSH/GSSG ratios in plasma. BTBR showed significantly increased 
GSSG levels in the brain (T-test, *p < 0.05), but GSH levels were similar in both strains.  
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Figure 2.3 Differences in mRNA expression levels of GSH related enzymes in 
BTBR and C57 mice. RT-qPCR analysis of relative mRNA expressions of Gclc, Gclm, 
and Gsr from frontal cortices of BTBR and C57 mice. Gclc levels were similar, but 
BTBR showed significant decreases in Gclm and Gsr compared to C57 (T-test, *p < 
0.05).  
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2.3.3   EAAT3 expression in Frontal cortex 
The frontal cortex was dissected from a sagittally divided brain from each animal 
(n = 4 per strain) (Fig. 2.4). Brain homogenates were fractionated into membrane and 
cytosol, and Western blotting for EAAT3 was performed. Bands were normalized to 
GAPDH for cytosolic fraction and to β-actin for membrane fraction. BTBR mice exhibited 
significantly reduced EAAT3 expression in the frontal cortex when compared to the C57 
strain, both in cytosolic (T-test, ***p < 0.001), and membrane (T-test, *p < 0.05) 
fractions. After fluorescence immunostaining of EAAT3 (red, puncta) and NeuN (green) 
(Fig. 2.5A), double labeling of EAAT3 and NeuN showed that the EAAT3 positive cells 
were of neuronal lineage (scale bar = 50 μm; magnification = 20X). The BTBR strain 
additionally exhibited reduced EAAT3/NeuN staining (arrowheads) compared to the C57 
strain mice. The number of neurons expressing EAAT3 (Fig. 2.5B) were compared 
between BTBR and C57 from all layers in the frontal cortex and displayed as the ratio of 
EAAT3 expressing neurons over NeuN positive neurons. Representative 
immunostained images from three different brain sections per animal were counted (n = 
4), and revealed that BTBR showed a significantly lower number of neurons expressing 
EAAT3 compared to C57 mice (T-test, ***p < 0.001).  
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Figure 2.4 Differences in EAAT3 expression levels in BTBR and C57 mice. BTBR 
and C57 mice showed different levels of EAAT3 expression in frontal cortices. EAAT3 
expression was significantly decreased in BTBR mice both in cytosolic (T-test, ***p < 
0.001) (A), and membrane fractions (T-test, *p < 0.05) (B); suggesting impaired cysteine 
transport in neurons which may lead to BTBR mice being more vulnerable to drugs, 
xenobiotics and/or subsequent oxidative stress.  
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Figure 2.5 Differences in EAAT3 expression in the frontal cortices of BTBR and 
C57 mice. Fluorescence immunostaining of EAAT3 (red, puncta) and NeuN (green) in 
frontal cortex (A). Double labeling of EAAT3 and NeuN shows that EAAT3 positive cells 
are also NeuN positive. BTBR mice show fewer EAAT3/NeuN positive cells compared 
to C57 mice indicating lower cysteine availability in neurons in BTBR, suggesting lower 
GSH biosynthesis (scale bar = 50 μm; magnification = 20X). The number of neurons 
expressing EAAT3 (B) were compared between BTBR and C57 mice from all layers in 
frontal cortices in ratios of EAAT3 expressing neurons to NeuN positive neurons. Three 
images from three different brain sections per animal were used for counting (n = 4). 
BTBR mice showed significantly fewer neurons expressing EAAT3 compared to C57 
mice (T-test, ***p < 0.001) 
 
*** 
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Using genetic databases (Yates et al., 2016) for SNP (Single nucleotide 
polymorphism) analysis to investigate the reduced expression of EAAT3 seen in the 
BTBR mouse strain, we detected  two polymorphisms in the open reading frame 
upstream of the coding region (5’) of the mRNA when compared to the C57 strain (Fig. 
2.6). SNPs were identified in the BTBR mouse strain in chromosome sequence 
19:28835072-28835172. (5’) UTR variants are located at positions 19:28835122 and 
19:28835127 and are identified as rs247522204 and rs216783576, respectively.   
Contrary to the observed reduction in EAAT3 expression in the frontal cortex of 
BTBR mice, mRNA concentrations remained unchanged as revealed by RT-qPCR 
analysis demonstrating no significant fluctuations between the BTBR and C57 mice 
(Fig. 2.7).  
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Figure 2.7. Differences in mRNA expression levels of EAAT3 in BTBR and C57 
mice. RT-qPCR analyses of relative mRNA expression in Slc1a1 were assessed in 
frontal cortex of BTBR and C57 (n = 4). Slc1a1 mRNA expression levels were similar in 
BTBR and C57. 
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2.4     Discussion 
In the present study, BTBR mice were found to have significantly lower plasma 
sulfate levels (Fig. 2.2), replicating a previous report using this animal model of autism 
(Corley et al., 2012).  This biochemical characteristic should make BTBR mice useful for 
investigating the abnormal sulfation capacity (Waring et al., 1997) and decreased 
sulfate conjugation of acetaminophen (Alberti et al., 1999) found in autistic children as 
well as heparan sulfate deficiency in autistic postmortem brain tissue (Pearson et al., 
2013). We also found significantly higher GSSG in BTBR mice (Fig. 2.3) suggesting 
higher levels of oxidative stress under basal condition. Taken together these findings 
further support the view that the BTBR strain is a suitable model to investigate the 
potential contribution of early exposure to environmental insults when sulfation is 
primarily used for detoxification. 
While we also found significantly decreased EAAT3 protein expression in the 
frontal cortex of BTBR (Fig. 2.5 and 2.6), brain GSH, GSSG and the ratio of GSH/GSSG 
were not significantly different between the two mouse strains. These findings are 
inconsistent with others who have reported a close association between EAAT3 
mediated cysteine uptake and GSH homeostasis in the brain (Berman et al., 2011; 
Guitart et al., 2015; Trivedi et al., 2014; Zhang et al., 2016). However, we think there at 
least three possible explanations are for these discrepancies. The first may be due to 
the region of the brain we chose to investigate. While it is well-established that there are 
anatomical abnormalities in several regions of autism brain, including frontal cortex, 
hippocampus, amygdala and cerebellum (Amaral et al., 2008; Carper et al., 2005; Torun 
et al., 2015), we examined the frontal cortex in since this area is greatly involved in 
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social, language and executive functions affecting relevant behavioral phenotypes of 
autism observed in this BTBR strain (Ellegood et al., 2013). However, it is possible that 
frontal cortex GSH homeostasis is less dependent on optimal EAAT3 function than 
other brain areas with greater sensitivity to oxidative stress, such as the hippocampus, 
which has been demonstrated in EAAT3 knockout mice (Aoyama et al., 2006; Cao et 
al., 2012). Thus, it will be important to investigate EAAT3 transporter levels and GSH 
redox balance in other regions of brain that are relevant to autism in future studies. 
Second, because basal GSH levels in neurons are lower than those in astrocytes, 
microglia, and oligodendorocytes (Dringen et al., 1999; Hirrlinger et al., 2002), glial 
sources of GSH in the frontal cortex homogenates may have masked any neuronal 
GSH deficit associated with reduced EAAT3 expression. Third, compensatory 
upregulation of other known cysteine uptake systems in neurons, such as the neutral 
amino-acid transporter system (ASCT1) (Shafqat et al., 1993; Yamamoto et al., 2003), 
may help maintain GSH homeostasis when EAAT3 mediated cysteine transport is 
inadequate. This interpretation is consistent with those of (Li et al., 2011) who reported 
that 8-week old EAAT3 knockout mice exhibited no significant reductions in cortical 
GSH levels either before or after receiving middle cerebral artery occlusion despite 
having larger brain infarct volumes and worse neurologic deficits that did wild-type 
controls.  
Perhaps more important than GSH levels under basal conditions, we also 
observed a significant decrease in mRNA expression levels of Gclm and Gsr in the 
frontal cortex of BTBR mice when compared to the C57 strain (Fig. 2.4), which suggests 
a reduced ability to synthesize GSH efficiently and recycle GSSG to GSH. Gclm 
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knockout mice exhibited more extensive hepatic damage when overdosed with 
acetaminophen compared to wild-type mice (McConnachie et al., 2007). In addition, 
mice with suboptimal levels of Gsr are more prone to oxidative stress and its associated 
diseases (Harvey et al., 2009). Thus, overall, our findings suggest the BTBR strain will 
be more vulnerable to xenobiotic induced neurotoxicity due to the decreased mRNA 
expression of Gclm and Gsr. With this in mind, it has been demonstrated that SJL/J 
strain, a mouse model of autoimmunity, showed decreased levels of cortical GSH 
levels, decreased EAAT3 levels in CD4+ T cells and decreased levels of methionine 
synthase activity in the cortex upon thimerosal exposure (Waly et al., 2012). This 
suggests that decreased EAAT3 levels lead to diminished GSH antioxidant capacity 
during an oxidative insult, which may alter pre/postnatal epigenetic regulations via 
decreases in methionine synthase. 
The role of EAAT3 during brain development needs further investigation and the 
BTBR mouse strain may be a favorable animal model to study it’s potential involvement 
in autism pathophysiology. We found that the BTBR strain contains 2 polymorphisms in 
the open reading frame upstream of the coding region (5’) of the mRNA when compared 
to C57 mice. The untranslated region (UTR) of mRNA contains short sequence 
elements that typically control posttranscriptional regulation, and upstream open reading 
frames (uORF) have been demonstrated to reduce protein levels in approximately 100 
eukaryotic genes (Calvo et al., 2009). Additionally, three human diseases are known to 
be caused via a mutation in the uORF (Liu et al., 1999; Wen et al., 2009; Wiestner et 
al., 1998), and a handful of diseases have been tentatively linked to mutations in the 
uORF that have been detected in patients but have yet to be tested with population 
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controls (Calvo et al., 2009). SNP analysis of EAAT3 additionally reported many 
upstream gene variants in the BTBR mouse strain when compared to that of C57 (Fig. 
2.7). De novo CNVs (Copy Number Variants) reportedly appear more frequently in 
autism spectrum disorders (ASD) than controls and likely develop in the germ line, 
making these CNVs unidentifiable in genetic studies with a familial design (Voineagu, 
2012).  SNPs that are reported to be associated with ASD are regularly located in the 
intergenic region of DNA (Voineagu, 2012), thus providing further support of EAAT3 
involvement with ASD. However, due to complex nature of autism and the likelihood 
that ASD involves multiple genome-environment interactions, it is critical to determine if 
the SNP found in the uORF of EAAT3 in the BTBR mouse strain (and all uORF 
mutations in general) is influenced and/or regulated via both environmental conditions 
and signaling pathways (Voineagu, 2012). It has been suggested that oxidative stress 
subsequently affecting the cytosolic GSH/GSSG ratio could result in S-glutathionylation 
of various proteins and apoptosis (Daniel et al., 2011), although our data show no 
significant changes in the ratio between the two strains. However, in support of our 
findings, reactive oxygen species and oxidative stress have been shown to significantly 
increase protein failure rates and unfolded protein numbers (Daniel et al., 2011). 
Furthermore, redox fluctuations in the intracellular region has been shown to affect gene 
translation (Aoyama et al., 2015); additionally, oxidative stress has been previously 
reported to reduce EAAT3 activity (Waly et al., 2012). 
With EAAT3 protein expression being reduced (Fig. 2.5 and 2.6), and mRNA 
concentrations remaining at normal levels in the BTBR strain (Fig. 2.8), it is possible 
that oxidative stress caused by improper sulfation subsequently effects the protein 
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product and not the mRNA transcribed. However, EAAT3 is immensely regulated via 
neuronal activity and intracellular signaling pathways, such as PI3K, and such 
regulation can occur both post-transductionally and post-translationally (Nieoullon et al., 
2006). Additionally, SNP analysis further verifies post-transcriptional modification due to 
EAAT3 showing a polymorphism in the post-transcriptional regulatory area (5’ upstream 
of the coding region) (Fig. 2.7). These data suggest that the mRNA levels of EAAT3 
observed in the BTBR strain do not correlate with EAAT3 protein expression, and that 
the reduced protein expression observed occurs post-transcriptionally. Moreover, it is 
evident that our sample size was not adequate enough to give a power for this particular 
experiment; thus, there may be changes in mRNA expressions of EAAT3 with larger 
number of samples. The regulatory molecules of EAAT3 need to be further elucidated to 
determine their role in EAAT3 transporter protein expression and function.  
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CHAPTER 3 
Early exposure to APAP induces changes in adolescent mice 
 
3.1 Introduction  
Autism is a neurological developmental disorder that occurs in early years of life 
and lasts lifetime. Autism is characterized by deficits in social interaction and 
communication, as well as restricted and repetitive behavior (Kidd, 2002; Klaiman et al., 
2015). Furthermore, autistic individuals may have other comorbidities (i.e., intellectual 
disabilities and depression), which can add to the burden of caregivers managing the 
patients’ challenge to carry out normal daily life (Bitsika et al., 2015). Due to the 
heterogeneity and complexity of the disease, prevention and cure for autism remains 
elusive. Therefore, autistic individuals and their families suffer from economic burden to 
provide special education and behavioral intervention in addition to basic medical needs 
(Bitsika et al., 2015; Chauhan et al., 2015; Klaiman et al., 2015). There are several 
genes that are associated with the development of autism, although it is strongly 
suggested that autism may be caused in concert with genetic, biological and 
environmental factors (Geier et al., 2009; Rossignol et al., 2012).  
Early acetaminophen (APAP) exposure is one of the environmental factors that is 
suggested to be linked to autism etiology. Epidemiological studies indicate that chronic 
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exposure to APAP during pregnancy may be associated with autism and ADHD-like 
behavior (Andrade, 2016; Avella-Garcia et al., 2016; Liew et al., 2014; Thompson et al., 
2014). Reports also suggest that there is an association between APAP administration 
in early childhood and developmental disorders, including autism (Bauer et al., 2013; 
Schultz et al., 2016; Shaw, 2013). Additionally, it was shown that chronic APAP 
administration caused alterations of amino acids levels in brain (Blecharz-Klin et al., 
2014), implicating that APAP can affect neurotransmission and it may lead to changes 
in normal brain function. Furthermore, APAP exposure can induce oxidative stress and 
mitochondrial dysfunction (da Silva et al., 2012). Taken together, this evidence suggest 
that APAP administration may alter homeostasis in brain, and may be involved in 
neurobehavioral changes. However, more thorough investigations are essential to prove 
the link between APAP exposure and neurodevelopment.  
It is well known that the BTBR T+tf/J (BTBR) mouse strain mimics autism 
spectrum disorder (ASD) phenotypes and it exhibits three core behavioral symptoms: 
impaired social interaction, anxiety, and repetitive behavior. BTBR mice also have a 
complete lack of the corpus callosum (Blanchard et al., 2012; Meyza et al., 2012; Meyza 
et al., 2013), and reduced heparin sulfate in the subventricular zone (SVZ) of the lateral 
ventricles (LV) (Blanchard et al., 2012; Mercier et al., 2012; Meyza et al., 2012).  In 
chapter 2, we reported that BTBR strain had significantly lower plasma sulfate levels, as 
well as lower EAAT3 expression in the frontal cortex compared to the C57 strain. 
Sulfation is the major metabolic pathway for APAP clearance, especially in the pediatric 
population (Miller et al., 1976). Moreover, lower levels of EAAT3 expression suggests 
that cysteine cannot be readily transported from extracellular space as needed. Based 
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on this data, we hypothesized that lower sulfate levels and EAAT3 expression would 
increase susceptibility to APAP toxicity, thereby exacerbating autistic features in BTBR 
strain compared to the C57 strain. To determine the changes with APAP administration, 
we injected APAP to neonatal mice and assessed changes in behaviors at adolescent 
age.   
 
3.2       Materials and methods 
3.2.1    Animal housing and maintenance 
All animal experiments were approved by the USF institutional Animal Care and 
Use Committee (IACUC). Breeding pairs of C57 BL/6 (C57) and BTBR mice were 
obtained from Jackson Laboratory (Bar Harbor, ME). Animals were housed in an animal 
facility of the University of South Florida (USF). All animals were given standard chow 
and water ad libitum.  
 
3.2.2   Drug treatments  
One female mouse per male mouse was kept in same cage for mating and the 
presence of plug was checked regularly to confirm gestation. Pregnant mice were 
separated from the male mice and kept in new cages. Starting at 7 postnatal days 
(PND), pups were treated with APAP. 100 mg/kg APAP (APAP100) or phosphate 
buffered saline (PBS) as a vehicle were administered or via intraperitoneal (I.P.) 
injection daily for 7 days. The exact doses were calculated based on body weights 
measured a day ahead of the drug administration. Following the drug administration 
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period, mice were weaned at 21 PND and housed until 3 month old age for behavioral 
tests. After the behavioral tests, mice were scarified and plasma and brain samples 
were collected for further analysis.  
 
3.2.3   Open Field 
The open field test was used as a standard test of general locomotor activity. 
Animals were monitored over a 15 min period, under moderate lighting conditions, in a 
40-cm square open field arena and assessed using ANY-maze video tracking software 
(Stoelting Co., Wood Dale, IL). General locomotor activity levels were evaluated by 
measurements of time mice spent during exploration of the open field arena. For 
horizontal activities, the total distance, the distance in the center of the arena, and the 
time spent in the center of the arena were analyzed using the data collected from the 
software. Additionally, the time spent during rearing and grooming were hand scored 
from videos. 
 
3. 2.4   Elevated Plus Maze 
Anxiety levels were assessed through the elevated plus maze (EPM). The EPM 
apparatus consists of two open arms (35 cm) and two enclosed arms (30.5 cm) each 
facing each other. Each arm is attached to a center platform (4.5 cm square) and 
elevated 40 cm off the floor. The mouse was placed in the center platform and allowed 
to explore for 5 min. Video tracking software measured movements in each section and 
arm entry determined when 100% of the body enter the arm.    
 50 
 
3.2.5 Social Interaction  
The test mouse was first placed in the center chamber of a three-chambered 
apparatus and allowed to explore the entire chamber for a 5 min habituation period with 
the doorways into the two side chambers open. For sociability test, the test mouse was 
enclosed in the center compartment and a novel mouse (an unfamiliar mouse of the 
same strain and gender) was enclosed in one of two wired cups positioned in each of 
the side chambers. The doors were re-opened and the subject mouse was allowed to 
explore the entire box for 10 min. For social novelty test, doors were closed and another 
novel mouse was placed in the wired cup in the opposite side of chamber. The doors 
were re-opened and the subject mouse was allowed to explore for another 10 min. Data 
were collected manually by two un-biased observers by measuring the time spent in 
each chamber during both sociability and social novelty sessions.  
 
3.2.6   Fear Conditioning  
Fear conditioning was used to assess associative memory function. Mice were 
placed in a 25 cm x 25 cm chamber with a wire grid flooring. During training session, 
mice were paced in the chamber for 7 min and freezing behavior was monitored 
throughout all testing phases. At 3 min and 5 min, mice received a mild foot shock (0.5 
mA, unconditioned stimulus) for the last 2 sec of a 30 sec tone (80 db tone, acoustic 
conditioned stimulus). 24 hr after the training session, mice were tested again for 3 min 
without stimuli for contextual test. After that, we placed the mice in a novel context to 
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perform a cued test. During the cued test, mice were allowed to explore the novel 
chamber for first 3 min followed by 3 min with acoustic tone. Freezing behavior was 
determined when mice present lack of motion for at least 2 consecutive sec.  
 
3.2.7   EAAT3 expression by immunoblotting  
We performed Western blotting to test changes in EAAT3. Tissues were 
homogenized in ice-cold lysis buffer (Sigma-Aldrich, St. Louise, MO) on ice. 
Homogenates were centrifuged at 14,000 g for 20 min at 4 C and the supernatant was 
obtained for protein quantification and other experiments. Protein concentration was 
determined using the bicinchoninic acid assay (PierceTM BCA protein assay kit, Pierce 
Biotechnology, Rockford, IL) for normalization. 30 μg protein was loaded onto 10% 
SDS-PAGE gels, then transferred onto nitrocellulose membrane followed by 1 hr 
blocking with 5% non-fat dry milk in PBS. Membranes were incubated with rabbit anti-
EAAT3 antibody (MABN1129, Sigma-Aldrich, St. Louis, MO) and mouse anti-β tubulin 
(ab7792, Abcam, Cambridge, MA) overnight at 4 C. After washing with 0.1% Tween 20 
containing PBS, membranes were incubated with secondary antibodies for 1 hr and 
visualized with Odyssey® Infrared Imaging system (LI-COR Biotechnology, Lincoln, NE). 
Band intensities of EAAT3 were normalized to β-tubulin bands as a loading control.    
 
3.2.8   EAAT3 expression by immunohistochemistry  
For immunostaining, sagittally transected brains were fixed overnight in 4% 
paraformaldehyde (PFA) at 4 C. Samples were then transferred to 30% sucrose 
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solution until the tissues no longer float. The brains were cryo-sectioned into 30-μm 
thick sections. Tissue sections were blocked with 4% normal goat serum and incubated 
with rabbit anti-EAAT3 antibody (1:1000, Sigma-Aldrich, St. Louise, MO) and mouse 
anti-NeuN antibody (1:2000, Abcam, Cambridge, MA) overnight at 4 C. Tissues were 
washed with 0.1% Triton x-100 containing PBS for 10 min three times. Tissues were 
incubated with Alexa fluor 488 conjugated goat anti-rabbit and Alexa fluor 594 
conjugated goat anti-mouse secondary antibodies for 1 hr at room temperature. Tissues 
were mounted with VECTASHIELD DAPI hardset mounting media (Vectorlab, 
Burlingame, CA). Fluorescence images were obtained with Zeiss microscope at 20X 
magnification.  
To quantify the expression levels of EAAT3 and NeuN, tissue slides were 
scanned using a slide scanning microscope (Zeiss). Obtained digital images were 
analyzed using Zeiss Neuroquant IAE analysis software. Regions of interest (ROI) were 
drawn on the slide images to assess frontal cortex and hippocampus areas. An 
experimenter defined thresholds of positive pixel intensity for both 488 and 597 
channels to determine positive staining within the given areas. Each tissue was 
automatically analyzed based on the threshold setup using a batch processing tool. The 
mean positive area within ROI was quantified by the software and used to compare ratio 
of EAAT3 expression to the expression of NeuN.  
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3.2.9   Statistical analysis 
Data are presented as mean ± SEM. In the most cases, comparisons were made 
between strains and drug treatments by Two-way ANOVA analysis followed by 
Bonferroni post-hoc test. Otherwise, another test is specified as needed. A value of p < 
0.05 was considered significant. We used the power analysis to determine the sample 
size of 16 per group for each strain (C57 and BTBR) to result at least 80% power, at α-
level of 0.05.    
 
3.3      Results 
 
3.3.1   Effect of neonatal APAP exposure on behavioral phenotypes in adolescence 
To determine if neonatal APAP exposure causes a behavioral phenotype in 
adolescent age, we administered APAP 100 mg/kg on 7 PND and each day thereafter 
for a total of 7 days. After the administration period, mice were housed until 3 months 
old age. Mice were then subjected to series of behavioral tests including open field, 
elevated plus maze, social interaction and fear conditioning. First, we measured general 
locomotor activities using open field. 100 mg/kg APAP administration did not cause 
changes in general locomotor activities (Fig. 3.1). However, significant differences were 
observed between C57 and BTBR mice. BTBR mice travelled significantly longer 
distance compare to C57 (***p < 0.001 for vehicle group, *p < 0.05 for APAP100 group). 
Also, BTBR mice showed significantly increased distance travelled in the center zone 
(*p < 0.05 for vehicle). High activity levels in the center zone of the open field area 
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indicate lower anxiety level (Heredia et al., 2014; Prut et al., 2003). We also performed 
EPM to further validate this finding. As a result, BTBR mice showed a trend of lower 
anxiety in the vehicle group, and showed significantly lower anxiety levels in APAP100 
group (**p < 0.01) compare to the same group of C57 mice (Fig. 3.2). Furthermore, we 
manually collected data on spontaneous vertical activities by measuring total time in 
rearing and total time in self-grooming from videos produced by the ANY-Maze program. 
While APAP exposure did not cause changes compared to the vehicle, the total rearing 
time (Fig. 3.1D) was significantly decreased in BTBR mice compare to C57 in both 
vehicle and APAP100 groups (C57 vs. BTBR, ***p <  0.001). Also, the time spent 
grooming (Fig. 3.1E) was also measured and showed that BTBR mice spent 
significantly longer time self-grooming in APA100 groups (C57 vs. BTBR, *p < 0.05).  
Amongst the behavioral symptoms of autism, impairment in social skills is the 
core behavioral deficit and it is often used as a diagnostic criteria to distinguish from 
other neurodevelopmental disorders (Deckers et al., 2014; Holloway et al., 2014).  To 
determine whether neonatal APAP exposure leads to exacerbated autistic features 
during adolescence, we performed the three-chambered social interaction test. Overall, 
100 mg/kg APAP did not cause changes in social behavior compared to vehicle in both 
C57 (Fig. 3.3A) and BTBR mice (Fig. 3.3B). During the sociability test that assessed if 
the subject mouse interacts with the stranger mouse, we found that BTBR mice spent 
less time in the side of chamber with the stranger mouse than in the empty chamber 
regardless of treatment groups (*p < 0.05). The behavioral phenotypes of BTBR mice 
have been studied extensively, and our finding was comparable with others (Blanchard 
et al., 2012; Scattoni et al., 2013; Sforazzini et al., 2014). In the social novelty session, a 
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new stranger mouse was placed in the empty cage while the old/familiar stranger 
mouse stayed in the same side of chamber. As a result, the time spent with familiar 
mouse and new stranger mouse were similar in both C57 (Fig. 3.3C) and BTBR mice 
(Fig. 3.3D), regardless of drug treatment groups.  
We also performed fear conditioning test to determine associative memory 
function by exposing mice to the auditory cue (tone, conditioned stimulus) and aversive 
stimulus (electric foot shock, unconditioned stimulus). The fear memory is assessed by 
the amount of freezing behavior, operationally defined as 2 sec of complete inactivity 
and stillness. During training session, the freezing behavior was comparable between 
C57 (Fig. 3.4A) and BTBR (Fig. 3.4B) strains, as well as between drug treatment groups. 
During the contextual fear conditioning test (Fig. 3.4C), BTBR mice demonstrated 
significantly lower freezing behaviors compared to C57 mice in both treatment groups 
(***p < 0.001). In addition, BTBR strain also showed lower freezing behaviors overall 
during cued fear conditioning test (Fig. 3.4D) regardless of the presence of the tone 
(***p < 0.001). This finding of decreased in associative memory function in BTBR 
compared to the control strain is in agreement with others (MacPherson et al., 2008; 
Yang et al., 2012).  
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Figure 3.1 C57 and BTBR showed unchanged locomotor activities with APAP 
exposure. The effects of APAP exposure on general locomotor activities were analyzed 
as locomotor. Overall, mice exposed to APAP 100 mg/kg did not show significant 
differences in general locomotor activities. However, BTBR strain showed a significant 
increase in total distance traveled (A) in the open field compare to C57 in both vehicle 
(C57 vs. BTBR, ***p < 0.001) and APAP100 groups (C57 vs. BTBR, *p < 0.05). Also, 
BTBR strain showed a significant increase in the distance travelled in the center (B) 
compared to C57 vehicle (*p < 0.05), while the time spent in center (C) did not show 
significant changes. For spontaneous vertical activities, the total rearing time (D) was 
measured and showed significantly lower rearing activities in BTBR mice compare to 
C57 in both vehicle and APAP100 groups (C57 vs. BTBR, ***p < 0.001). The time spent 
grooming (E) was also measured and showed that BTBR mice spent significantly longer 
time self-grooming in APAP100 groups (C57 vs. BTBR, *p < 0.05) 
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Figure 3.2 Changes in anxiety levels in C57 and BTBR mice. Both C57 and BTBR 
did not show changes in anxiety levels between vehicle and APAP100 groups. However, 
BTBR mice that received APAP 100 mg/kg spent significantly longer time in the open 
arm compared to C57 mice in same treatment group (**p < 0.01).   
 
 
 
 
 
 
 
 
 
 58 
Figure 3.3 Social behaviors of adolescent C57 and BTBR mice. In sociability test (A 
and B), C57 mice (A) spent time in the chamber with stranger similar to the empty 
chamber regardless of treatment. BTBR (B) showed significant less time spent with 
stranger mouse than in the empty chamber both in vehicle (two-tailed t-test, *p < 0.05) 
and APAP100 groups (two-tailed t-test, *p < 0.05). Social novelty (C and D) was 
assessed using another new stranger mouse and measured the time spent with either 
the familiar mouse or new stranger mouse. C57 mice (C) spent similar amount of time in 
the chamber with new stranger mouse and with familiar mouse. BTBR mice (D) also 
spent similar amounts of time in each chamber, regardless of treatment. In APAP100 
group, BTBR spent significantly less time with new stranger mouse compare to C57 
(two-tailed t-test, ††p < 0.01) 
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Figure 3.4 Differences in contextual and cued fear conditioning between C57 and 
BTBR mice. Freezing behavior during the training session is shown in panel A for C57 
and B for BTBR, and the freezing behavior is comparable with strains and treatment 
groups. Arrows on both panels indicate the time that a tone and a foot shock occurred 
(3 min and 5 min). Although there were no differences between treatment groups in 
both C57 and BTBR mice with the contextual fear conditioning test (C), BTBR mice 
showed significantly less freezing behaviors compare to C57 mice in both treatment 
groups (***p < 0.001). Similarly, APAP did not affect freezing behavior during the cued 
conditioning test in both strains, but BTBR showed significantly reduced freezing 
behavior compared to C57 regardless of the presence of the tone (***p < 0.001).  
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3.3.2 Effect of neonatal APAP exposure in EAAT3 expression levels in adolescence 
In chapter 2, we reported that BTBR strain had significantly lower EAAT3 
expression levels in frontal cortex. Based on this observation, we determined if early 
exposure to APAP caused differences in EAAT3 expression levels in frontal cortex as 
well as in hippocampus. To assess EAAT3 expression, we immunostained brain tissues 
with EAAT3 and NeuN (neuronal marker) together (Fig. 3.5, 3.6 and 3.7), and we also 
performed western blotting to further validate our findings (Fig. 3.8).  
We compared C57 (Fig. 3.5A) and BTBR (Fig. 3.5B) mice. BTBR showed 
decreased EAAT3 expression levels in both the frontal cortex (Fig. 3.5C, two-tailed t-
test, *p < 0.05) and hippocampus (Fig. 3.5D, two-tailed t-test, **p < 0.01). It has been 
reported that EAAT3 expression was high in the hippocampus and the neurons in 
hippocampus were more vulnerable to oxidative stress (Aoyama et al., 2006). This 
finding is also in agreement with our western blot data (Fig. 3.8) showing significantly 
decreased EAAT3 expression levels in brain homogenate of BTBR mice compared to 
C57 mice.  
Next, we compared vehicle and APAP100 groups in each strain. For C57 mice 
(Fig. 3.6), there were no significant changes in both the frontal cortex and the 
hippocampus, a finding supported by our western blot data (Fig. 3.8). While the 
APAP100 group of the C57 strain seemed to have lower EAAT3 expression than the 
vehicle, it was not significant (t-test, p = 0.0674). Parallel to this experiment, we also 
measured EAAT3 expression in BTBR mice to determine if APAP administration caused 
changes in the expression levels of EAAT3. As a result, APAP100 group showed 
significantly elevated EAAT3 in both the frontal cortex (Fig 3.8C, t-test, *p < 0.05) and 
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the hippocampus (Fig. 3.8D, t-test, *** p < 0.001) compare to vehicle. Similarly, BTBR 
showed elevated EAAT3 expression levels in APAP100 in hippocampus (Fig. 3.8B). 
These findings suggest that early exposure to APAP even at the therapeutic doses may 
alter normal brain development, with changes still evident in adolescence.  
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Figure 3.5 EAAT3 and NeuN expression in the frontal cortex and hippocampus of 
C57 and BTBR mice. Images from C57 (A) and BTBR (B) are shown (20X, 100X 
magnification). The quantification of EAAT3 expression was calculated by ratio of 
EAAT3 signal intensity to NeuN signal intensity. As a result, BTBR showed significantly 
reduced EAAT3 expression compared to C57 in both the frontal cortex (FC, panel C, 
two-tailed t-test, *p < 0.05) and the hippocampus (HC, panel D, two-tailed t-test, **p < 
0.01). Scale bar = 50 μm. 
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Figure 3.6 EAAT3 and NeuN expression in C57 mice.  Images from C57 mice with 
vehicle group (A) and APAP100 group (B) are shown. Results showed that there were 
no significant changes between vehicle and APAP100 groups both in the frontal cortex 
(FC) (C) and the hippocampus (HC) (D). Scale bar = 50 μm. 
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Figure 3.7 EAAT3 and NeuN expression in BTBR mice. Images from BTBR mice 
with vehicle group (A) and APAP100 group (B) are shown. Results showed that the 
expression of EAAT3 was significantly increased in APAP100 group in both the frontal 
cortex (FC, panel C, two-tailed t-test, *p < 0.05) and the hippocampus (HC, panel D, 
two-tailed t-test, ***p < 0.001). Scale bar = 50 μm. 
 
 65 
 
Figure 3.8 Expression of EAAT3 and NeuN levels in brain homogenates. In the 
frontal cortex (A), there were no changes in the EAAT3 expression between vehicle and 
APAP100 groups both in the C57 and BTBR mice. However, vehicle group of the BTBR 
mice showed significantly lower EAAT3 expression levels compared to the vehicle 
group of C57 mice (*p < 0.05). In the hippocampus (B), there were no differences 
between vehicle and APAP100 group in C57 mice. The APAP100 group of BTBR 
showed significantly elevated EAAT3 expression levels compared to vehicle group (*p < 
0.05). In addition, the vehicle group of BTBR showed significantly lower EAAT3 
expression level compared to the vehicle group of C57 (†p < 0.05).  
 
 
 
 
 
 66 
3.4     Discussion 
In this chapter, we demonstrated that neonatal APAP exposure changes in 
behavioral phenotypes and EAAT 3 expression during adolescence.  We also showed 
that the changes are greater in the BTBR mouse strain compared to C57 due to the 
lower plasma sulfate levels and EAAT3 expressions in brain. As our results show, we 
did not observe significant differences in mouse behaviors in adolescent mice between 
vehicle groups and APAP100 groups of both strains. This may be due to the dose of 
APAP used in our experiments.  
For example, a study showed significant changes in brain amino acid levels after 
long-term administration with APAP at therapeutic dose in Wistar rats; which may be an 
important evidence that APAP administration may alters neurotransmission in the brain 
leading to abnormal behavioral phenotypes (Blecharz-Klin et al., 2014). Also, it was 
suggested that acute administration of repeated doses of APAP at the therapeutic dose 
range at PND 10 caused alterations in locomotor activities in adulthood as well as 
changes in brain derived neurotrophic factor (BDNF) in different regions of brain at PND 
10 (Viberg et al., 2014). Taken together, these findings suggest that APAP 
administration alters essential factors during normal brain development and it may lead 
to abnormal behaviors. There was a recent study that tested acute exposure to 100 
mg/kg APAP at 3 to 4 month old age, and showed increases in social behavior in these 
BTBR mice (Gould et al., 2012). Even though this study reported the opposite effects of 
APAP in BTBR mice with the increase in social behavior, it is still relevant to current 
study as it demonstrates that acute APAP exposure at the therapeutic dose alters 
behavioral changes. We may see a discrepancy since the experimental design of the 
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above study differed from the current study. The above study used acute exposure and 
tested behaviors within 1 hr. This change in assessment time could lead to robust and 
more evident behavioral changes, compared to our 3-month analysis point. Thus the 
100 mg/kg changes may induce immediate changes, but possibly not sustained after a 
longer period of time (i.e. 3 months). 
 We then measured EAAT3 expression in the frontal cortex as well as in the 
hippocampus to assess if EAAT3 expression is altered in response to APAP exposure. 
Overall, early exposure to APAP caused elevated EAAT3 expression in the frontal 
cortex and hippocampus in the BTBR mice, but not in the C57 strain. This finding may 
be a compensatory mechanism to increase intracellular cysteine levels for GSH 
production.  
 We also compared the EAAT3 expression and behavioral phenotypes of the C57 
and BTBR mice. First, we were able to validate the findings from chapter 2 showing 
lower expression levels of EAAT3 in the frontal cortex and hippocampus. In addition, 
although we were not able to show significant changes with 100 mg/kg APAP 
administration, we observed differences in behavioral phenotypes between C57 and 
BTBR mice. With open field test, BTBR mice showed elevated repetitive behaviors as 
shown in self-grooming behavior. Also, we observed lower anxiety levels in BTBR mice. 
These results are in agreement with others (Amodeo et al., 2012; Molenhuis et al., 
2014). BTBR strain is known to have architectural abnormalities with corpus callosum 
agenesis and reduced hippocampal commissures, the brain regions that connect both 
hemispheres and hippocampi, respectively (Bohlen et al., 2012; Sforazzini et al., 2014; 
Wahlsten et al., 2003). These architectural abnormalities have been reported to be 
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associated with less responsiveness in contextual and cued fear conditioning 
(MacPherson et al., 2008; Schimanski et al., 2002). We also determined that BTBR 
strain tends to show less freezing behavior in both contextual and cued fear 
conditioning; suggesting impaired associative memory in BTBR mice. 
There have been an increasing number of human association studies that link 
APAP exposure and autism; suggesting prenatal exposure to APAP causes 
hyperactivity and attention deficit (Andrade, 2016; Avella-Garcia et al., 2016; Becker et 
al., 2010; Liew et al., 2014; Thompson et al., 2014) . Although our finding did not 
support the hypothesis that early APAP exposure at therapeutic doses causes autistic 
like behavior in mice during adolescence, they will be important to consider in designing 
future investigations.  
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CHAPTER 4 
Acetaminophen induced toxicity in neonatal mice 
 
 
4.1     Introduction  
 
As described in chapter 1, acetaminophen (APAP) is one of the most popular 
over-the-counter drugs that possesses both antipyretic and analgesic effects. It is 
considered a relatively safe and effective pharmaceutical agent when used at 
recommended therapeutic doses. However, intentional/unintentional overdose and 
chronic use of APAP can cause serious skin reactions, liver failure, and even death 
(Botting, 2000; Dahlin et al., 1984).  
Approximately 10 to 15% of APAP is metabolized by cytochrome P450 2E1 (CYP 
2E1) to a highly electrophilic and toxic metabolite, N-acetyl-para-benzoquinoneimine 
(NAPQI). NAPQI covalently binds with the major endogenous antioxidant found in the 
body, glutathione (GSH), and as a result, NAPQI depletes available GSH stores. 
Excessive amounts of NAPQI can bind to DNA and proteins leading to cellular damage 
(Copple et al., 2008; Kalinec et al., 2014; Moore et al., 1985). Another metabolite, p-
aminophenol (4AP), is produced by deacetylation of APAP by the liver and can be found 
in the liver, kidney and brain. Emerging evidence shows that APAP can cross the blood-
brain-barrier (BBB) and cause neurotoxicity through its metabolites (Gould et al., 2012; 
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Hogestatt et al., 2005). However, the mechanism of 4AP-induced toxicity is not clear, 
especially in the brain (McConkey et al., 2009). 
The brain is more prone to oxidative stress because of its high oxygen 
consumption rate; this leads to increased free radical production. Being composed of a 
high concentration of polyunsaturated fatty acids also makes it a target for lipid 
peroxidation. The availability of major endogenous antioxidants, such as GSH, is 
important to balance redox homeostasis. As NAPQI and 4AP are known to deplete GSH 
in the liver and kidney, it is possible that APAP administration will dose-dependently 
disrupt GSH homeostasis in the brain resulting in increased oxidative stress.  
APAP may adversely affect the brain, particularly during early development, 
when it is prescribed to children to lessen fever or irritability after vaccination during the 
first year of life. While there is evidence for cytotoxic effects of APAP and its metabolites 
in cultured cortical neurons (Schultz et al., 2008), it is unclear if APAP exerts its effects 
on the brain during development and how this may lead to developmental disorders. 
Based on the existing evidence, we hypothesized that early exposure to APAP 
administration will dose-dependently induce cellular damage and oxidative stress by 
disrupting GSH homeostasis. To test this hypothesis, we used C57 and BTBR mouse 
strains for early exposure to APAP administration. In human studies, the half-life of 
APAP was prolonged in neonates and younger children compared to adults, which 
increased the chance for its accumulation in the plasma (Arana et al., 2001). This study 
also indicated that repeated doses over short time periods may cause high APAP 
plasma levels, which could be toxic due to accumulation of its metabolites, NAPQI and 
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4AP. In this study, we determined if sub-chronic doses of APAP administration induce 
neurotoxicity in vivo. 
 
4.2     Materials and methods 
 
4.2.1   Animal housing and maintenance 
All animal experiments were approved by the USF institutional Animal Care and 
Use Committee (IACUC). Breeding pairs of C57 BL/6 (C57) and BTBR mice were 
obtained from Jackson Laboratory (Bar Harbor, MA). Animals were housed in the 
animal facility at the University of South Florida (USF). All animals were given standard 
chow and water ad libitum.  
 
4.2.2   Drug treatments  
One female mouse per male mouse was kept in same cage for mating and the 
presence of plug was checked regularly to confirm gestation. Pregnant mice were 
separated from the male mouse and kept in new cages. Starting at 7 postnatal days 
(PND), pups were treated with APAP. Animals were administered with phosphate 
buffered saline (PBS) as a vehicle, 100, 200 and 300 mg/kg APAP via intraperitoneal 
(I.P.) injection daily for 7 days. The exact doses were calculated based on body weights 
measured a day ahead of the drug administration.   
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4.2.3   Tissue preparation  
Mice were sacrificed approximately 2 hours from the last drug administration. 
Syringes were coated with EDTA to collect blood samples via cardiac puncture. Blood 
samples were transferred to clean tubes and centrifuged at 14,000 g for 15 min to 
obtain plasma. Brain tissues were collected and frozen immediately in liquid nitrogen. 
All samples were kept in -80 C until assays. Tissues were homogenized in ice-cold 
lysis buffer (Sigma, St. Louis, MO) on ice. Homogenates were centrifuged at 14,000 g 
for 20 min at 4 C and the supernatant was collected for protein quantification and other 
experiments. Protein amount was determined using the bicinchoninic acid assay 
(PierceTM BCA protein assay kit, Pierce Biotechnology, Rockford, IL) for normalization.     
 
4.2.4   ALT assay  
Alanine aminotransferase (ALT) activity was measured using ALT fluorometric 
assay kit (BioVision, Inc., Milpitas, CA) following the manufacturer’s instructions. 
Plasma samples were diluted in assay buffer; 20 μL of the samples and standards were 
loaded onto a 96 well microplate. Following, 100 μL of the enzyme and substrate 
mixture was added to each well. Fluorescent intensity was measured using a microplate 
reader at 535/587 nm (Ex/Em). The plate was read at 5 min (T1) and at 60 min (T2) 
after incubating the plate at 37 C. The obtained fluorescent intensity units were 
calculated based on the pyruvate standard curve and converted to nmol of pyruvate. 
The obtained pyruvate amount was divided by (time x initial sample volumes) to 
calculate enzyme activity. 
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4.2.5   AST assay  
Aspartate aminotransferase (AST) activity was measured using AST activity 
colorimetric assay kit (BioVision, Inc., Milpitas, CA) according to the manufacturer’s 
instructions. Brain homogenates and plasma samples were loaded onto a 96-well plate. 
Reaction mixture composed with AST substrate, AST enzyme and AST developer were 
added and optical density was measured at 450 nm. Optical density was measured at 5 
min (T1). The plate was incubated at 37 C for 60 min (T2) and optical density was 
measured again. As a product of this enzyme reaction, glutamate was used as a 
standard. The generated glutamate from each sample was calculated based on the 
glutamate standard curve and the amount was divided by (time x initial sample 
volumes) to calculate enzyme activity.  
 
4.2.6   GSH/GSSG assay  
Total and reduced GSH was measured using glutathione fluorescent detection kit 
(Arbor AssaysTM, Ann Arbor, MI) according to the manufacturer’s instructions. First, 
frozen tissues and plasma samples were thawed on ice. Brain tissues were gently 
rinsed with ice-cold PBS and the right hemispheres were homogenized with ice-cold 
100 mM phosphate buffer (pH 7.0). Homogenates were centrifuged at 14,000 g for 10 
min at 4 C and supernatants were collected. 5% sulfosalicylate was added to each 
aliquoted sample (both tissue homogenates and plasma) and incubated on ice for 10 
min followed by centrifugation for deproteination. Supernatant was collected and diluted 
with assay buffer. 50 μL of samples and standards were plated onto a 96 well plate and 
25 μL of the ThioStar® reagent was added to measure reduced GSH concentration. 
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Fluorescent readings were obtained at 510/370 nm (Ex/Em) after incubating for 15 min 
at room temperature. For total GSH, 25 μL of a reaction mixture (glutathione reductase 
and NADPH) was added to convert GSSG to GSH. Treated samples were allowed to 
react for 15 min at room temperature and fluorescent signals were read again. GSSG 
concentrations were calculated by subtracting the amount of reduced GSH from the 
amount of total GSH and dividing by 2.  
 
4.2.7   GPx activity assay  
Glutathione peroxidase (GPx) enzyme activity was measured using GPx assay 
kit (BioVision, Inc., Milpitas, CA) following manufacturer’s instruction. In this assay, GPx 
reduces Cumene hydroperoxide while oxidizing GSH to GSSG. The GSSG is reduced 
back to GSH by glutathione reductase using NADPH as a proton donor. The decreased 
NADPH is measured at 340 nm and is proportional to GPx activity. 
 
4.2.8   GST activity assay  
Glutathione-s-transferase (GST) activity was measured using GST assay kit 
(Sigma-Aldrich, St. Louis, MO). In this assay, GST conjugates glutathione and 1-Chloro-
2,4-dinitrobenzene (CDNB). Brain homogenates and plasma samples were loaded onto 
a 96-well plate, and the mixture of CDNB and GSH was added to start the enzyme 
reaction.  Absorbance was measured at 340 nm at 0 min (T1) and 60 min (T2). The 
increased absorbance is proportional to GST enzyme activity and the difference 
between T2 and T1 is divided by the reaction time. 
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4.2.9   Enzyme-linked immunosorbent assay (ELISA) for HNE adducts  
 4-hydroxy-2-nonenal (HNE) is one of the biomarkers of lipid peroxidation and it is 
an indicative of elevated oxidative stress. HNE adducts were measured using 
OxiSelectTM HNE adduct competitive ELISA (Cell Biolabs, Inc., San Diego, CA) per 
manufacturer’s instruction. Brain homogenates were loaded onto a HNE conjugate 
coated plate. After 1 hour incubation with anti-HNE polyclonal antibody, HRP 
conjugated secondary is added. After visualization with substrate solution, absorbance 
was measured at 450 nm. The amount of HNE adducts were calculated based on the 
standard curve generated using HNE standards. Also, data was normalized by total 
protein amount determined by BCA protein assay.   
 
4.2.10   Statistical Analysis  
Data was presented as mean ± standard error of mean (SEM). Analysis of 
variance (ANOVA) was used, followed by post hoc comparison using Bonferonni’s 
method for multiple variables.  The α-levels were set at 0.05 for all analyses. The 
GraphPad version 5.0 was used for statistical analysis and to assess significance within 
the data.  
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4.3      Results 
 
4.3.1    APAP administration causes toxicity in neonatal mice 
 
 
Mice were exposed to three different doses of APAP (APAP 100, 200 and 300 
mg/kg) and vehicle starting at postnatal day 7 (PND 7). APAP was administered daily 
via I.P. injection for 7 days. The three doses were calculated based on the equation 
which uses standardized conversion factors for body mass (FDA, 2005). APAP 100 
mg/kg (APAP100) is considered to be safe; while 200 mg/kg is seen as a high dose, but 
still falls in the range of a safe dose. APAP administered at 300 mg/kg is a toxic dose in 
infants. The toxicity of APAP was determined by calculating mortality rate (Fig. 4.1) 
which was done by Kaplan-Meier analysis with a log-rank test. During the 10-day 
observation period, both C57 (Fig. 4.1A) and BTBR (Fig. 4.1B) mice showed 
significantly increased mortality rate at 200 and 300 mg/kg groups in a dose dependent 
manner (***p < 0.001). The groups that received the toxic dose of APAP (300 mg/kg) in 
both C57 and BTBR showed the highest mortality rate at 100% (n = 11) and 69.23% (n 
= 13), respectively. The mice receiving 200 mg/kg of APAP showed mortality rate at 
61.5% (n = 13) and 37.5% (n = 16) for C57 and BTBR. In the lowest dose group of 
APAP100, C57 showed 16.67% (n = 12), while BTBR showed 0% mortality rate at the 
same dose (n = 15). Both vehicle groups did not show mortality. Based on this result, 
our working dose was adjusted to 100 mg/kg as higher doses caused fatality. Later, 150 
mg/kg dose group was added as 100 mg/kg dose did not show increased toxicity levels.  
To investigate if the repeated doses increased toxicity of APAP, both plasma and 
brain homogenates were collected at day 1 and day 7. ALT and AST levels were 
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measured to determine APAP induced liver damage using plasma. While ALT is strictly 
produced from the liver as a sign of toxicity, AST is produced from other organs as well 
including brain (Hertz et al., 2017; Pérez-Mato et al., 2016). ALT levels were similar 
between vehicle groups and APAP100 groups in both C57 and BTBR strain, and both at 
day 1 and day 7; suggesting no sign of liver toxicity at 100 mg/kg dose. Plasma levels of 
AST (Fig. 4.2B) only increased in the APAP100 mg/kg group of BTBR mouse strain at 
day 1 compared to vehicle (n = 4, *p < 0.05). In the brain (Fig. 4.2A), the BTBR mice 
treated with APAP100 showed significantly elevated AST levels compared to vehicle at 
day 1 (n = 4, **p < 0.01) compared to C57 at the same dose (n = 4, ###p < 0.001).  
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Figure 4.1 Mortality rate of C57 and BTBR mice with APAP administration. Kaplan-
Meier analysis with a log-rank test was used to compare each treated group (n = 10-16 
in each group). Both C57 (A) and BTBR (B) showed significantly increased mortality 
rate dose dependently (***p < 0.001).  
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Figure 4.2 ALT levels in plasma. Both C57 (A) and BTBR (B) strains showed 
unchanged ALT levels between vehicle and APAP100 groups. At day 1, C57 (A) 
showed significantly elevated ALT levels in both vehicle and APAP treated groups (n = 
4, **p < 0.01) compare to day 7. 
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Figure 4.3 AST levels in the brain and plasma. In the brain (A), AST levels were 
significantly elevated in BTBR mice that received APAP100 compared to the vehicle (n 
= 4, **p < 0.01). Also, the BTBR 100 group showed significantly elevated AST levels 
compared to C57 strain which received same dose (n = 4, ###p < 0.001). In plasma (B), 
the BTBR strain that received APAP100 showed significantly elevated AST levels 
compared to BTBR vehicle. At day 7, both C57 and BTBR mice showed similar levels of 
AST in brain and plasma. 
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4.3.2   APAP disturbs GSH homeostasis in neonatal mice  
 
APAP is metabolized in the liver and GSH is associated with detoxification of 
APAP and its metabolites as described in Chapter 1; therefore we measured GSH and 
GSSG in plasma and brain homogenates. In brain homogenates (Fig. 4.4), GSH and 
GSSG levels were not different between groups (Fig 4.4A, first and second panels), but 
GSSG (Fig. 4.4A, second panel) was significantly elevated between day 1 and day 7 
when treated with APAP100 in C57 (n = 4, **p < 0.01). In BTBR mice (Fig 4.4B), GSH 
levels did not fluctuate as seen in C57 mice, but GSSG levels were significantly 
elevated between day 1 and day 7 with APAP administration (n = 4, *p < 0.05).  
In plasma, GSH levels were also similar between treatment groups (Fig 4.5A and 
B, first panels) both in C57 and BTBR. C57 mice, contrary to what we observed in the 
brain homogenates, GSSG levels were decreased in APAP100 treated mice compared 
to the vehicle (n = 4, *p < 0.05). In addition, the ratio of GSH to GSSG was significantly 
increased compared to the vehicle (n = 4, ***p < 0.001), and APAP100 group at day 1 
(n = 4, #p < 0.05) due to the decreased in GSSG levels. In BTBR mouse (Fig. 4.5B), 
plasma levels of GSH and GSSG showed a trend towards an increase in both GSH and 
GSSG at day 7 with APAP100 group, but it was not significantly different.  
Even though our data shows some significant changes in GSH and GSSG levels, 
it doesn’t show robust changes between treatment groups. Based on the toxicity data 
(Fig. 4.1, 4.2 and 4.3), 100 mg/kg dose may not change GSH and GSSG. Therefore, we 
chose another dose at 150 mg/kg to confirm if the supratherapeutic dose induced any 
changes in GPx, GST enzyme activities and 4-hydroxynonenal (HNE) adducts levels.  
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For GPx activity (Fig. 4.6), GPx activities were significantly elevated with 150 
mg/kg APAP (APAP150) administration in all groups (n = 4, *p < 0.05, ***p < 0.001); 
suggesting that GPx activities were required to convert elevated levels of peroxides with 
APAP150 in the brain. In addition, APAP100 group of BTBR showed significantly 
decreased GPx activities at day 7 compare to day 1 (n = 4, ‡p < 0.01). Also, APAP100 
group in BTBR strain showed significantly elevated GPx activity compare to the same 
dose group of C57 (n = 4, †p < 0.05) at day 1.  For GST activity (Fig. 4.7), both C57 and 
BTBR showed similar levels of GST activity between treatment doses and durations in 
brain homogenates (Fig. 4.7A). However, in the plasma (Fig. 4.7B), APAP100 and 
APAP150 groups in C57 showed significantly higher GST activity compared to vehicle 
(n = 4, *p < 0.05) at day 7; which suggests increased levels of detoxification via GST 
with APAP administration. In addition, BTBR APAP150 showed significantly higher GPx 
activity compared to C57 (n = 4, †p < 0.05).  
Lastly, levels of HNE adducts were measured in the brain homogenates. HNE 
adducts levels were significantly elevated in APAP 150 groups compared to the vehicle 
(**p < 0.01) and APAP100 groups (*p < 0.05) C57 strain at day 7(A). Also, APAP150 
group in BTBR (Fig. 4.8) showed significantly elevated HNE adducts levels at both day1 
(*p < 0.05, compare to vehicle) and day 7 (*p < 0.05, compare to APAP100; **p < 0.01, 
compare to vehicle). These elevated HNE adducts may indicate that APAP150 may 
cause oxidative stress in the brain. Additionally, HNE adducts levels in APAP150 group 
were significantly higher in day 7 than in day 1 (††p < 0.01). 
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Figure 4.4 GSH, GSSG and GSH/GSSG in pup brain homogenates. C57 mice (A) 
showed similar GSH levels, but significantly different GSSG levels between day 1 and 
day 7 with APAP treated group (n = 4, **p < 0.01). BTBR mice (B) also showed similar 
GSH levels, but showed significantly elevated GSSG level at day 7 compared to day 1 
when treated with APAP (n = 4, *p < 0.05).  No differences were observed in the ratio of 
GSH to GSSG in both C57 and BTBR strains.  
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Figure 4.5 GSH, GSSG and GSH/GSSG in plasma. GSH levels were similar in both 
C57 (A) and BTBR (B) strains. In C57 strain, GSSG levels were significantly lower in the 
APAP100 group at day 7 compared to the vehicle (n = 4, *p < 0.05).  Additionally, the 
ratio of GSH to GSSG was significantly elevated in the APAP100 group compared to 
vehicle at day 7 (n = 4, ***p < 0.001), and compared to APAP 100 group at day 1 (n = 4, 
#p < 0.05).  
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Figure 4.6 GPx activity assay in pup brain homogenates. Overall, GPx activities 
were significantly elevated with APAP150 administration in all groups (n = 4, *p < 0.05, 
***p < 0.001). In addition, APAP100 group of BTBR showed significantly decreased GPx 
activities at day 7 compare to day 1 (n = 4, ‡p < 0.01). Also, APAP100 group in BTBR 
strain showed significantly elevated GPx activity compare to the same dose group of 
C57 (n = 4, †p < 0.05) at day 1.  
 
 
 
 
 
 
 
‡ 
† 
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Figure 4.7 GST activity in brain and plasma. In brain (A), both C57 and BTBR 
showed similar levels of GST activity between treatment doses and durations. In plasma 
(B), APAP100 and APAP150 groups in C57 showed significantly higher GST activity 
compared to vehicle (n = 4, *p<0.05) at day 7. In addition, BTBR APAP150 group 
showed significantly higher GST activity compared to C57 at day 1 (n = 4, †p<0.05). 
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Figure 4.8 Levels of HNE adducts in the brain after APAP administration. HNE 
adduct levels were significantly elevated in APAP150 groups compared to the vehicle (n 
= 4, **p < 0.01) and APAP 100 groups (n = 4, *p < 0.05) at day 7 in C57 strain (A). In 
BTBR (B), APAP150 group showed significantly elevated HNE adduct levels at day1 (n 
= 4, *p < 0.05, compare to vehicle) and day 7 (n = 4, *p < 0.05, compare to APAP 100; n 
= 4, **p < 0.01, compare to vehicle). Additionally, HNE adduct levels in APAP150 group 
were significantly higher in day 7 than in day 1 (††p < 0.01).  
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4.4      Discussion  
 
APAP is recommended after vaccination to reduce fever and irritability in infants 
and young children. It is known to safe within the therapeutic doses; however, due to 
the repeated doses often used, unintentional overdose, and poor detoxification 
capability in pediatric population, APAP induced toxicity in pediatric population has been 
reported (Leonis et al., 2013). We postulate that APAP may cause changes in brain, 
even with non-toxic doses. We investigated if APAP administration at sub-chronic doses 
1) would be toxic to neonatal mice, and 2) if C57 and BTBR mice respond differently to 
this treatment due to the diminished plasma sulfate levels and EAAT3 expression levels 
in the brain as shown in chapter 2. Pups at 7 PND were treated with APAP at different 
doses for 7 days via I.P. injection. In our study, we hypothesize that repeated 
physiologically safe doses of APAP would cause changes in the brain.  
The human clinical doses for APAP administration are determined based on 
weight, especially in the pediatric population. The doses for animals are not well 
established in mice, therefore we calculated the experimental doses based on the 
formula that uses body mass constant for the dose conversion from animal to human 
(FDA, 2005). Children (ages one to two) are recommended within a 24 hour period to 
have 5 maximum doses of 10 to 15 mg/kg of APAP (Leonis et al., 2013). Using the 
formula, 100 mg/kg animal dose is equivalent to 10 mg/kg human dose. Three doses of 
100 mg/kg, 200 mg/kg and 300 mg/kg were chosen and administered for 7 days starting 
at 7 PDN. As a result, two higher doses induced high mortality (Fig. 4.1).   
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In addition, we showed that APAP100 did not induce tissue damage using ALT 
and AST levels (Fig. 4.2 and 4.3). However, there was an increase in AST levels seen 
in brain homogenates of BTBR mice. This suggests that APAP induced changes in the 
brain without causing liver damage in neonatal BTBR mice. AST is also referred to as 
glutamic oxaloacetic transaminase (GOT). In the brain, it is known to play a role in 
balancing glutamate homeostasis by degrading glutamate using oxaloacetate as a co-
factor; therefore, elevated AST activity has shown to be associated with decreased in 
glutamate levels, exerting neuroprotective effect (Pérez-Mato et al., 2016; Teichberg et 
al., 2009; Zhang et al., 2016). Perhaps, the elevated AST in the brain homogenates of 
BTBR mice is a compensatory mechanism.  
Furthermore, we investigated if APAP at the therapeutic doses caused changes 
in GSH levels. As stated in chapter 1, APAP is metabolized by CYP 2E1, an enzyme is 
also expressed in brain. APAP crosses the blood brain barrier and is known to disrupt 
endocannabinoid signaling through another metabolite, para-aminophenol (4AP) 
(Dalmann et al., 2015; Hogestatt et al., 2005; Yisarakun et al., 2014). We measured 
plasma and brain levels of GSH, GSSG, and its ratio (GSH/GSSG). In C57 mice, 
APAP100 did not exert significant changes in GSH levels compared to vehicle in both 
plasma and brain (Fig. 4.4 and 4.5). However, GSSG levels were elevated significantly 
in brain homogenates at day 7 compared to day 1 (Fig. 4.4), and plasma GSSG levels 
were significantly decreased (Fig. 4.5) in C57. GSSG, the oxidized glutathione, is the 
by-product generated when GPx converts hydrogen peroxide to water. Therefore, 
increased GSSG is associated with elevated oxidative stress. The GSSG is then 
reduced back to GSH by glutathione reductase (GR) to maintain GSH pool. The 
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decreased GSSG in plasma may be the sign of reduced levels of oxidative stress. 
However, elevated GSSG in brain homogenates for both C57 and BTBR mice may 
suggest increase in oxidative stress, GPx or GR activity. From our data. There was no 
increase in GPx activity with APAP100 in both mouse strains (Fig. 4.6); thus, it may be 
linked to GR activity rather than GPx activity. To validate GR activity as a dependent 
factor future experiments are needed. Ultimately, 100 mg/kg APAP did not cause 
consistent changes in GSH and GSSG levels, therefore we believe that APAP100 is 
therapeutically safe. Thus, we included 150 mg/kg dose to determine if a 
supratherapeutic dose can change GPx and GST activity. Supratherapeutic dose of 
APAP (150 mg/kg) showed significant increase of GPx activity (Fig. 4.6). Also, plasma 
levels of GST activities were changed while brain levels were unchanged in both C57 
and BTBR. This suggests that 150 mg/kg may be safe but GSH balance may be 
affected.  
Our ultimate goal of this project was to determine if APAP administration during 
neonatal period caused oxidative stress due to the imbalance of the GSH system. 
Therefore, we measured HNE adducts levels, which is a lipid peroxidation markers. 
HNE levels have been implicated in numerous neurological disorder including autism 
(Kwon et al., 2007; Pecorelli et al., 2013; Romano et al., 2017). HNE is produced during 
lipid peroxidation by oxidation of n-6 fatty acids and elevated. Our results showed that 
HNE adducts were elevated primarily with APAP150 administration at day 7 in both C57 
and BTBR. This suggests that supratherapeutic dose of APAP may cause oxidative 
stress even though the dose is still considered to be safe. APAP is known to have a 
narrow therapeutic index (Budnitz et al., 2011; Claridge et al., 2010), thus erroneous 
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dosing may lead to serious side effects. There have been case studies which report 
possible side effects of APAP even with therapeutic doses (Claridge et al., 2010; Heubi 
et al., 1998; Moling et al., 2006).  
Overall, our data supports that APAP administration in children may increase 
oxidative stress and also negatively affect the GSH system even with safe doses. While 
this study is valuable in urging parents and caregivers to practice safety of APAP dose 
administration to young children, more thorough investigations are needed to further 
confirm the effects of APAP in the pediatric population.  
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CHAPTER 5 
Conclusion 
 
Autism is characterized by deficits in social interaction and communication, as 
well as restricted and repetitive behavior and are used to diagnose autism (Klaiman et 
al., 2015). The underlying cause of autism is still unclear, due to the heterogeneity and 
complexity of the disease; hence, it is hard to prevent and cure the disorder. While 
behavioral interventions and pharmacological therapies are used to ease the symptoms, 
there is still a need for the development of more effective diagnostic tools and therapies. 
In fact, the timing of diagnosis is critical for therapy outcomes (Bradshaw et al., 2015; 
Webb et al., 2014), especially with behavioral interventions; however, it is not easy due 
to the given heterogeneity of autism and the lack of specific biomarkers.  
BTBR is one of the inbred mouse strains, which exhibits three core behavioral 
characteristics of human autism clinical symptoms. These behavioral and 
neuroanatomical characteristics have been extensively studied (Amodeo et al., 2012; 
Blanchard et al., 2012; Meyza et al., 2013; Rutz et al., 2012; Sforazzini et al., 2014). 
Although the mechanism underlying the behavioral deficits still need to be elucidated, 
this particular mouse strain may be suitable for developing more specific biomarkers 
and therapies. In this context, we examined plasma sulfate levels and cortical excitatory 
amino acid transporter 3 (EAAT3) expression in BTBR mice compared to C57 mice. In 
chapter 2, we reported a reduction in plasma sulfate levels in BTBR mice compared to 
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C57 mice. The deficiency of sulfate and/or dysfunctional sulfate physiology has been 
associated with autism in certain populations (Alberti et al., 1999; Bowling et al., 2013; 
Geier et al., 2009). Because sulfate availability is important for detoxification of 
xenobiotics during pediatric years, reduced sulfation may be a risk factor for autism by 
making individuals more prone to xenobiotics induced toxicity (Schultz et al., 2016). The 
idea of synergistic interactions between genetics and environmental factors is now 
widely accepted; therefore, these features are particularly important in testing various 
environmental factors that are implicated in the underlying cause of autism.  
Another important finding in chapter 2 is that the BTBR strain had significantly 
lower cortical EAAT3 levels. EAAT3, plays an important role in maintaining intracellular 
cysteine levels in neurons (Watts et al., 2014). Neurons utilize cysteine to produce 
glutathione (GSH) to combat oxidants and/or toxins. In fact, GSH is an essential 
antioxidant in cells and plays a pivotal role in maintaining redox homeostasis (Schmidt 
et al., 2012), and a dysfunctional GSH system has been implicated in autism (Dukhande 
et al., 2009; Gu et al., 2013). Since intracellular transport of cysteine in neurons is 
required to synthesize GSH (Watts et al., 2014), the reduced cortical EAAT3 levels may 
affect overall redox homeostasis in the brain. Therefore, our finding of reduced cortical 
EAAT3 levels is important and the BTBR strain may be a useful animal model to study 
oxidative stress, GSH system dysfunction, the role of EAAT3 and cysteine often linked 
to abnormal behaviors relevant to autism.  
The overall results from chapter 2 provide evidence of both reduced neuronal 
expression of EAAT3 and plasma sulfate levels in the BTBR mouse strain. In addition, 
we observed reduced brain mRNA expression levels of Gclm and Gsr, and an increase 
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in GSSG in plasma. While we found no differences in GSH levels and the ration of 
GSH/GSSG in the plasma and the brain under basal conditions, taken all together our 
findings suggest BTBR mice have increased vulnerability to oxidative stress due to the 
diminished detoxification capacity.  
Furthermore, there has been an increase in the number of human associated 
studies linking early APAP exposure and autism as well as other neurobehavioral 
disorders (Andrade, 2016; Carter et al., 2016; Schultz et al., 2016; Schultz et al., 2008; 
Seneff et al., 2012; Shaw, 2013). Also, studies suggest that prenatal exposure to APAP 
through maternal drug intake may cause abnormal behaviors in children, as well as 
increasing prevalence in idiopathic autism (Andrade, 2016; Avella-Garcia et al., 2016; 
Becker et al., 2010; Liew et al., 2016; Liew et al., 2014; Thompson et al., 2014). Even 
though there is a growing interest in the possible link between early APAP exposure 
and autism from both scientific/non-scientific communities, more research is needed to 
determine if there is a causal relationship.  
To investigate the effects of APAP on brain development, neonatal mice received 
100 mg/kg APAP for 7 days and were subjected to behavioral tests at 3 month old age. 
Contrary to what we hypothesized, overall behavior did not show differences between 
vehicle and 100 mg/kg APAP. We think this contradictory is due to the dose and 
duration of APAP administration. Based on what we observed, we believe increasing 
the dose to 150 mg/kg and/or increasing treatment duration may alter behavioral 
phenotypes (later explored in chapter 4). Beside the results from the behavioral tests, 
we observed increased expression levels of EAAT3 in the frontal cortex and the 
hippocampus. Perhaps, the elevated EAAT3 level is a compensatory action in response 
` 95 
to APAP administration; however, more thorough investigation is needed to uncover the 
role of EAAT3 in autism pathophysiology as well as neurodevelopment. Additionally, 
although we did not find alterations in behavioral phenotypes due to early APAP 
exposure at therapeutic doses, we were able to validate the behavioral characteristics 
of the BTBR strain compared to C57 showing that BTBR mice tend to show increased 
repetitive behaviors, less anxiety and decreased associative memory function. 
In chapter 4, to investigate whether the BTBR strain responds differently to 
xenobiotics compared to the C57 strain, we tested several doses of acetaminophen 
(APAP) in neonatal mice. APAP is the most popular over-the-counter fever reducer and 
pain killer. It is considered safe at therapeutic doses, but the safety of this drug has not 
been fully investigated in the pediatric population. While human clinical doses are 
calculated based on body weights in the pediatric population, more thorough 
investigations are required since children detoxify and eliminate APAP via a different 
mechanism than adults (Miller et al., 1976). APAP is metabolized in the liver and 
converted to toxic metabolites. Then these toxic metabolites are eliminated via sulfation 
and glucuronidation (Ganetsky et al., 2013). In the pediatric population, sulfation is the 
major route of detoxification of APAP, thus dysfunctional sulfation may lead to 
accumulation of toxic metabolites (Leonis et al., 2013; Miller et al., 1976). 
In this chapter, we initially tested 3 doses of APAP (100, 200, and 300 mg/kg) in 
neonatal mice via intraperitoneal (I.P.) injection for 7 days. The therapeutic dose (100 
mg/kg) did not induced mortality, but 200 mg/kg and 300 mg/kg doses induced high 
mortality rate. Therefore, we proceeded with the therapeutic dose, which did not show 
toxicity and did not alter GSH levels. Later we evaluated a supratherapeutic dose (150 
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mg/kg), which showed changes in GSH related enzyme activities and increased 
oxidative stress markers in the brain homogenates. This finding is very important since 
this dose is considered to be safe and therapeutic. It has been suggested that repeated 
dosing within a short time (< 4 hr) and chronic use of APAP, even at the therapeutic 
dose, may cause liver toxicity (Heubi et al., 1998). These observations should be used 
to educate the public on the importance of proper APAP doses used in the pediatric 
population.  
We suggest that the findings from this study are sufficient to urge the public in 
the use of APAP for pediatric population. Overall, this study suggests that 1) BTBR 
strain might be suitable as a mouse model to investigate the potential contribution of 
early exposure to various environmental insults when sulfation is primarily used for 
detoxification, 2) sub-chronic administration of APAP at therapeutic dose during 
neonatal period did not alter behavioral phenotypes, but it may alter antioxidant capacity 
in the brain, and 3)  APAP may alter normal brain development at the supratherapeutic 
dose by changing important enzymes involved in antioxidant activity and detoxification.  
Our study has laid the foundation for future prospective research designed to 
better understand the APAP and autism association in humans. First, based on our 
results from the supratherapeutic dose (150 mg/kg) in chapter 4, future studies should 
include the supratherapeutic dose to confirm alterations in behavioral phenotypes. 
APAP100 groups did not show changes in behavioral phenotypes in C57 nor did it 
worsen the autistic behaviors in BTBR mice in chapter 3. The 150 mg/kg of APAP dose 
however, may affect animal behaviors since we observed elevated GPx activity and 
elevated HNE adduct levels. Interestingly, the 150 mg/kg dose still falls within the 
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therapeutic range, and it would be important to test the supratherapeutic doses in 
relation to neurodevelopmental changes. Furthermore, the duration of APAP 
administration could be adjusted to be longer and/or repetitive. In our study, we used 
daily I.P. injection for 7 days. Based on the observations made in humans, it is 
implicated that chronic administration and/also repeated dosing may increase side 
effects of APAP (Heard et al., 2014; Leonis et al., 2013).  
In the future, measuring plasma and brain levels of APAP and its metabolites will 
be important to ensure there is a production of the toxic metabolites. These metabolites 
are thought to cytotoxic (Hogestatt et al., 2005; Kalinec et al., 2014; Nassini et al., 2010; 
Schultz et al., 2012). This will be helpful to establish therapeutic and toxic doses of 
APAP in mice, thus enabling more efficient research. Second, measurements of GSH 
and GSSG appear to be largely non-significant in our data, therefore more sensitive 
methodologies using different types of derivatizations and more sensitive detection 
could assist in more precise and accurate analysis. Lastly, we could develop a battery 
of behavioral tests to further assess memory and cognitive functions in BTBR mice as 
we saw decreases in associative memory function in BTBR mice in chapter 3. Because 
BTBR mice have reduced hippocampal commissure as one of the anatomical hallmarks 
(Mercier et al., 2012), and we found reduce hippocampal EAAT3 expression (chapter 3), 
it will be important for future research to investigate if EAAT3 is associated with memory 
and cognitive functions.  
 Taken all together, we suggest that our study showed that APAP may have the 
potential to have an effect on normal brain development. As addressed above, the 
overall impact of APAP is dependent on its doses, duration and repeated 
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administrations. Addressing these variables and their effect on autism may be critical to 
aid human translational research. Nonetheless, the association between APAP and 
autism is still controversial, and more investigations are essential to aid in the safety of 
APAP administration in the pediatric population.  
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